| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.966 | 0.002 | 0.966 | Aldehyde oxidase inhibitor | 0.781 0.005 DBMET00863 0.84 0.004 DBMET00864 0.627 0.015 DBMET02815 0.785 0.005 DBMET02816 0.738 0.006 DBMET02817 0.807 0.004 DBMET02818 0.686 0.009 DBMET02820 0.287 0.07 DBMET02819 0.326 0.06 DBMET02821 0.589 0.02 DBMET02822 0.232 0.089 DBMET02823 0.337 0.058 DBMET02824 | ||
| 0.805 | 0.003 | 0.805 | Vasodilator | 0.742 0.004 DBMET00863 0.578 0.007 DBMET00864 0.254 0.067 DBMET02815 0.553 0.008 DBMET02817 0.794 0.003 DBMET02818 0.683 0.004 DBMET02820 0.694 0.004 DBMET02819 | ||
| 0.603 | 0.016 | 0.675 | Vasodilator, peripheral | 0.589 0.017 DBMET00863 0.483 0.031 DBMET00864 0.33 0.083 DBMET02815 0.273 0.112 DBMET02816 0.47 0.035 DBMET02817 0.675 0.008 DBMET02818 0.195 0.182 DBMET02820 0.299 0.098 DBMET02819 | DBMET02818 | |
| 0.551 | 0.005 | 0.551 | Pyruvate kinase inhibitor | 0.334 0.039 DBMET00863 0.327 0.041 DBMET00864 0.154 0.112 DBMET02814 0.163 0.105 DBMET02815 0.311 0.045 DBMET02816 0.291 0.05 DBMET02817 0.394 0.021 DBMET02818 0.27 0.056 DBMET02820 0.284 0.052 DBMET02821 0.38 0.025 DBMET02822 0.18 0.093 DBMET02823 0.355 0.032 DBMET02824 | ||
| 0.546 | 0.002 | 0.546 | Myeloperoxidase inhibitor | 0.235 0.004 DBMET00863 0.162 0.009 DBMET00864 0.153 0.01 DBMET02815 0.19 0.006 DBMET02816 0.144 0.012 DBMET02817 0.352 0.003 DBMET02818 0.197 0.005 DBMET02820 0.116 0.022 DBMET02819 | ||
| 0.548 | 0.022 | 0.566 | Streptokinase A inhibitor | 0.539 0.023 DBMET00863 0.382 0.052 DBMET00864 0.234 0.113 DBMET02817 0.524 0.025 DBMET02818 0.566 0.02 DBMET02820 0.565 0.02 DBMET02819 | DBMET02820 | |
| 0.538 | 0.023 | 0.538 | Angiogenesis inhibitor | 0.401 0.053 DBMET00863 0.229 0.139 DBMET00864 0.249 0.124 DBMET02815 0.347 0.072 DBMET02816 0.261 0.115 DBMET02817 0.348 0.072 DBMET02818 0.424 0.046 DBMET02820 0.283 0.102 DBMET02819 0.288 0.099 DBMET02824 | ||
| 0.5 | 0.01 | 0.509 | Peroxidase inhibitor | 0.208 0.057 DBMET00863 0.273 0.043 DBMET00864 0.422 0.018 DBMET02815 0.509 0.009 DBMET02816 0.148 0.079 DBMET02817 0.479 0.011 DBMET02818 0.197 0.06 DBMET02820 0.188 0.063 DBMET02819 0.252 0.047 DBMET02822 0.152 0.077 DBMET02824 | DBMET02816 | |
| 0.477 | 0.033 | 0.691 | GABA C receptor rho-3 antagonist | 0.485 0.03 DBMET00863 0.384 0.069 DBMET00864 0.569 0.011 DBMET02814 0.583 0.009 DBMET02815 0.691 0.003 DBMET02816 0.305 0.112 DBMET02817 0.353 0.084 DBMET02818 0.415 0.055 DBMET02820 0.28 0.13 DBMET02819 0.6 0.007 DBMET02821 0.597 0.008 DBMET02822 0.435 0.047 DBMET02823 0.596 0.008 DBMET02824 | DBMET02816 | |
| 0.469 | 0.048 | 0.469 | 15-Lipoxygenase inhibitor | 0.313 0.123 DBMET00863 0.441 0.057 DBMET00864 0.266 0.152 DBMET02816 0.405 0.072 DBMET02818 0.211 0.201 DBMET02822 | ||
| 0.429 | 0.013 | 0.485 | Cyclic AMP phosphodiesterase inhibitor | 0.485 0.008 DBMET00863 0.345 0.027 DBMET00864 0.288 0.047 DBMET02814 0.404 0.016 DBMET02815 0.353 0.025 DBMET02816 0.24 0.068 DBMET02817 0.435 0.012 DBMET02818 0.254 0.062 DBMET02820 0.252 0.063 DBMET02819 0.344 0.027 DBMET02821 0.379 0.02 DBMET02822 0.299 0.042 DBMET02823 0.228 0.075 DBMET02824 | DBMET00863 | |
| 0.396 | 0.031 | 0.396 | Hypoxia-inducible factor 1 alpha inhibitor | 0.344 0.047 DBMET00863 0.22 0.129 DBMET00864 0.225 0.124 DBMET02814 0.278 0.078 DBMET02816 0.278 0.078 DBMET02818 0.211 0.139 DBMET02822 0.281 0.076 DBMET02824 | ||
| 0.362 | 0.013 | 0.362 | DNA methyltransferase I inhibitor | 0.141 0.114 DBMET00864 0.21 0.064 DBMET02816 0.182 0.079 DBMET02817 0.257 0.044 DBMET02818 0.144 0.11 DBMET02820 | ||
| 0.446 | 0.097 | 0.579 | Alpha-glucosidase inhibitor | 0.501 0.08 DBMET00863 0.362 0.13 DBMET00864 0.487 0.084 DBMET02818 0.549 0.066 DBMET02820 0.579 0.059 DBMET02819 | DBMET02819 | |
| 0.387 | 0.043 | 0.519 | Spasmolytic | 0.181 0.136 DBMET00863 0.168 0.147 DBMET00864 0.251 0.091 DBMET02815 0.19 0.128 DBMET02816 0.519 0.021 DBMET02818 | DBMET02818 | |
| 0.347 | 0.017 | 0.347 | DNA methylase inhibitor | 0.207 0.075 DBMET02816 0.163 0.106 DBMET02817 0.233 0.058 DBMET02818 | ||
| 0.326 | 0.011 | 0.353 | Aurora-A kinase inhibitor | 0.353 0.009 DBMET00863 0.135 0.047 DBMET00864 0.296 0.013 DBMET02815 0.147 0.041 DBMET02816 0.095 0.071 DBMET02817 0.266 0.016 DBMET02818 0.246 0.018 DBMET02820 0.234 0.02 DBMET02819 0.122 0.053 DBMET02824 | DBMET00863 | |
| 0.303 | 0.021 | 0.303 | Vascular endothelial growth factor antagonist | 0.277 0.025 DBMET00863 0.098 0.084 DBMET02815 0.165 0.049 DBMET02816 0.119 0.069 DBMET02818 0.242 0.03 DBMET02820 0.125 0.065 DBMET02819 0.14 0.058 DBMET02824 | ||
| 0.386 | 0.115 | 0.515 | Transcription factor inhibitor | 0.511 0.072 DBMET00863 0.239 0.194 DBMET00864 0.333 0.138 DBMET02814 0.324 0.142 DBMET02818 0.515 0.07 DBMET02820 0.444 0.093 DBMET02819 0.233 0.199 DBMET02821 | DBMET02820 | |
| 0.331 | 0.09 | 0.377 | Prostaglandin dehydrogenase inhibitor | 0.276 0.114 DBMET00863 0.377 0.074 DBMET02818 0.264 0.12 DBMET02821 0.283 0.11 DBMET02822 0.216 0.147 DBMET02823 0.183 0.17 DBMET02824 | DBMET02818 | |
| 0.283 | 0.043 | 0.501 | Tyrosine 3 hydroxylase inhibitor | 0.431 0.005 DBMET00863 0.501 0.004 DBMET00864 0.189 0.157 DBMET02814 0.262 0.058 DBMET02815 0.356 0.015 DBMET02816 0.433 0.005 DBMET02817 0.24 0.078 DBMET02818 0.261 0.058 DBMET02820 0.228 0.093 DBMET02819 0.226 0.095 DBMET02821 0.264 0.056 DBMET02822 0.213 0.114 DBMET02823 0.216 0.11 DBMET02824 | DBMET00864 | |
| 0.296 | 0.058 | 0.412 | Cardiotonic | 0.286 0.062 DBMET02815 0.412 0.027 DBMET02818 | DBMET02818 | |
| 0.235 | 0.028 | 0.238 | Vascular endothelial growth factor 2 antagonist | 0.238 0.028 DBMET00863 0.141 0.052 DBMET02816 0.09 0.079 DBMET02818 0.203 0.034 DBMET02820 0.106 0.068 DBMET02819 0.119 0.061 DBMET02824 | DBMET00863 | |
| 0.275 | 0.069 | 0.309 | Aryl hydrocarbon receptor agonist | 0.172 0.12 DBMET02815 0.309 0.058 DBMET02816 0.24 0.083 DBMET02818 | DBMET02816 | |
| 0.216 | 0.023 | 0.216 | Vascular endothelial growth factor 1 antagonist | 0.175 0.033 DBMET00863 0.115 0.057 DBMET02815 0.112 0.059 DBMET02816 0.133 0.048 DBMET02820 0.111 0.059 DBMET02824 | ||
| 0.287 | 0.098 | 0.322 | Antithrombotic | 0.194 0.184 DBMET02816 0.322 0.075 DBMET02818 | DBMET02818 | |
| 0.199 | 0.015 | 0.199 | Epidermal growth factor antagonist | 0.116 0.035 DBMET00863 0.1 0.045 DBMET02818 0.114 0.036 DBMET02820 | ||
| 0.214 | 0.034 | 0.323 | Cyclin-dependent kinase inhibitor | 0.099 0.091 DBMET00863 0.323 0.017 DBMET02815 0.249 0.027 DBMET02816 0.169 0.048 DBMET02818 0.16 0.051 DBMET02820 0.147 0.058 DBMET02819 0.246 0.028 DBMET02821 0.142 0.061 DBMET02822 0.118 0.075 DBMET02823 0.16 0.052 DBMET02824 | DBMET02815 | |
| 0.319 | 0.145 | 0.503 | 5 Hydroxytryptamine release inhibitor | 0.332 0.132 DBMET00863 0.347 0.117 DBMET00864 0.273 0.197 DBMET02814 0.463 0.046 DBMET02815 0.503 0.032 DBMET02816 0.275 0.195 DBMET02817 0.365 0.103 DBMET02818 0.355 0.111 DBMET02820 0.393 0.083 DBMET02819 0.264 0.209 DBMET02821 0.287 0.18 DBMET02822 0.291 0.176 DBMET02824 | DBMET02816 | |
| 0.181 | 0.008 | 0.198 | Alcohol oxidase inhibitor | 0.057 0.038 DBMET00863 0.115 0.015 DBMET00864 0.097 0.019 DBMET02815 0.198 0.007 DBMET02816 0.062 0.034 DBMET02817 0.144 0.011 DBMET02818 0.102 0.018 DBMET02820 0.078 0.025 DBMET02819 | DBMET02816 | |
| 0.199 | 0.029 | 0.209 | MAO A inhibitor | 0.209 0.027 DBMET00863 0.095 0.067 DBMET02816 0.115 0.055 DBMET02818 0.141 0.044 DBMET02820 0.084 0.077 DBMET02819 | DBMET00863 | |
| 0.174 | 0.005 | 0.408 | Maillard reaction inhibitor | 0.408 0.002 DBMET00863 0.105 0.015 DBMET00864 0.167 0.005 DBMET02818 | DBMET00863 | |
| 0.172 | 0.003 | 0.172 | Diamine oxidase inhibitor | 0.061 0.009 DBMET00863 0.057 0.011 DBMET02816 0.088 0.005 DBMET02818 0.069 0.007 DBMET02820 0.037 0.026 DBMET02819 | ||
| 0.336 | 0.167 | 0.543 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.346 0.155 DBMET00863 0.428 0.077 DBMET02814 0.485 0.041 DBMET02815 0.543 0.018 DBMET02816 0.35 0.151 DBMET02818 0.307 0.204 DBMET02820 0.317 0.19 DBMET02819 0.438 0.07 DBMET02821 0.287 0.231 DBMET02822 0.336 0.166 DBMET02823 0.459 0.056 DBMET02824 | DBMET02816 | |
| 0.208 | 0.044 | 0.381 | Growth factor antagonist | 0.132 0.082 DBMET00863 0.131 0.083 DBMET02815 0.219 0.041 DBMET02816 0.136 0.079 DBMET02818 0.149 0.07 DBMET02820 0.117 0.094 DBMET02819 0.243 0.036 DBMET02821 0.155 0.066 DBMET02822 0.381 0.019 DBMET02823 0.161 0.063 DBMET02824 | DBMET02823 | |
| 0.193 | 0.038 | 0.225 | Cyclin-dependent kinase 3 inhibitor | 0.188 0.042 DBMET00863 0.148 0.101 DBMET00864 0.2 0.033 DBMET02815 0.225 0.022 DBMET02816 0.189 0.041 DBMET02818 0.19 0.04 DBMET02820 0.188 0.042 DBMET02819 | DBMET02816 | |
| 0.23 | 0.076 | 0.583 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.211 0.086 DBMET00863 0.21 0.086 DBMET02814 0.549 0.009 DBMET02815 0.53 0.01 DBMET02816 0.275 0.057 DBMET02818 0.144 0.136 DBMET02819 0.33 0.04 DBMET02821 0.372 0.03 DBMET02822 0.217 0.083 DBMET02823 0.583 0.006 DBMET02824 | DBMET02824 | |
| 0.185 | 0.032 | 0.268 | Aldehyde dehydrogenase inhibitor | 0.103 0.092 DBMET02814 0.147 0.049 DBMET02815 0.268 0.015 DBMET02816 0.101 0.095 DBMET02817 0.104 0.091 DBMET02818 0.128 0.063 DBMET02821 0.179 0.034 DBMET02822 0.137 0.056 DBMET02823 0.125 0.066 DBMET02824 | DBMET02816 | |
| 0.157 | 0.005 | 0.157 | Cyclin B inhibitor | 0.112 0.008 DBMET02816 0.074 0.019 DBMET02818 | ||
| 0.181 | 0.033 | 0.181 | Epidermal growth factor receptor kinase inhibitor | 0.124 0.069 DBMET00863 0.111 0.083 DBMET02818 0.125 0.068 DBMET02820 | ||
| 0.225 | 0.084 | 0.576 | Dyrk kinase inhibitor | 0.208 0.094 DBMET00863 0.239 0.077 DBMET02814 0.559 0.009 DBMET02815 0.534 0.01 DBMET02816 0.288 0.057 DBMET02818 0.152 0.134 DBMET02819 0.321 0.045 DBMET02821 0.355 0.036 DBMET02822 0.206 0.095 DBMET02823 0.576 0.008 DBMET02824 | DBMET02824 | |
| 0.181 | 0.041 | 0.383 | GABA C receptor rho-2 antagonist | 0.189 0.036 DBMET00863 0.159 0.063 DBMET00864 0.215 0.022 DBMET02814 0.252 0.011 DBMET02815 0.383 0.004 DBMET02816 0.126 0.113 DBMET02817 0.127 0.111 DBMET02818 0.155 0.067 DBMET02820 0.243 0.013 DBMET02821 0.233 0.016 DBMET02822 0.175 0.046 DBMET02823 0.236 0.015 DBMET02824 | DBMET02816 | |
| 0.165 | 0.04 | 0.381 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.101 0.085 DBMET00863 0.109 0.078 DBMET02814 0.316 0.01 DBMET02815 0.381 0.006 DBMET02816 0.164 0.041 DBMET02821 0.124 0.065 DBMET02822 0.095 0.09 DBMET02823 0.232 0.02 DBMET02824 | DBMET02816 | |
| 0.165 | 0.04 | 0.38 | Abl kinase inhibitor | 0.1 0.085 DBMET00863 0.109 0.078 DBMET02814 0.315 0.01 DBMET02815 0.38 0.006 DBMET02816 0.164 0.041 DBMET02821 0.123 0.066 DBMET02822 0.094 0.09 DBMET02823 0.231 0.02 DBMET02824 | DBMET02816 | |
| 0.216 | 0.091 | 0.238 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.238 0.082 DBMET00863 0.166 0.125 DBMET02814 0.202 0.099 DBMET02816 0.189 0.107 DBMET02818 0.199 0.1 DBMET02824 | DBMET00863 | |
| 0.211 | 0.089 | 0.388 | Free radical scavenger | 0.245 0.071 DBMET00863 0.388 0.031 DBMET00864 0.279 0.058 DBMET02817 0.211 0.089 DBMET02818 0.183 0.112 DBMET02822 | DBMET00864 | |
| 0.22 | 0.101 | 0.446 | Antioxidant | 0.246 0.086 DBMET00863 0.365 0.042 DBMET00864 0.446 0.027 DBMET02817 0.236 0.092 DBMET02818 | DBMET02817 | |
| 0.116 | 0.005 | 0.116 | Guanylate cyclase stimulant | 0.067 0.012 DBMET00863 0.053 0.018 DBMET00864 0.04 0.039 DBMET02814 0.059 0.014 DBMET02817 0.061 0.013 DBMET02818 0.043 0.031 DBMET02820 0.041 0.036 DBMET02823 | ||
| 0.163 | 0.054 | 0.167 | MAO inhibitor | 0.166 0.053 DBMET00863 0.099 0.092 DBMET02815 0.167 0.053 DBMET02818 0.121 0.074 DBMET02820 0.127 0.071 DBMET02819 | DBMET02818 | |
| 0.15 | 0.046 | 0.187 | Cathepsin H inhibitor | 0.103 0.102 DBMET00863 0.162 0.039 DBMET02815 0.176 0.031 DBMET02816 0.187 0.026 DBMET02818 0.133 0.06 DBMET02820 0.172 0.033 DBMET02819 0.108 0.092 DBMET02824 | DBMET02818 | |
| 0.207 | 0.11 | 0.373 | Superoxide dismutase inhibitor | 0.21 0.107 DBMET00863 0.235 0.085 DBMET00864 0.222 0.096 DBMET02815 0.373 0.032 DBMET02816 0.181 0.14 DBMET02817 0.235 0.085 DBMET02820 0.172 0.153 DBMET02819 | DBMET02816 | |
| 0.263 | 0.165 | 0.263 | Antibacterial | 0.259 0.169 DBMET00864 0.226 0.2 DBMET02816 0.235 0.192 DBMET02818 0.228 0.198 DBMET02820 | ||
| 0.102 | 0.013 | 0.118 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.089 0.024 DBMET00863 0.081 0.035 DBMET02814 0.092 0.021 DBMET02815 0.118 0.006 DBMET02816 0.086 0.027 DBMET02818 0.075 0.048 DBMET02820 0.09 0.022 DBMET02821 0.098 0.015 DBMET02824 | DBMET02816 | |
| 0.13 | 0.043 | 0.178 | Xanthine oxidase inhibitor | 0.178 0.025 DBMET02815 0.146 0.036 DBMET02816 0.168 0.028 DBMET02818 0.122 0.047 DBMET02822 0.135 0.04 DBMET02824 | DBMET02815 | |
| 0.18 | 0.099 | 0.317 | Histone acetyltransferase inhibitor | 0.201 0.067 DBMET00863 0.218 0.046 DBMET02814 0.241 0.029 DBMET02815 0.266 0.02 DBMET02816 0.169 0.115 DBMET02820 0.317 0.011 DBMET02821 0.291 0.015 DBMET02822 0.202 0.066 DBMET02823 0.206 0.061 DBMET02824 | DBMET02821 | |
| 0.11 | 0.03 | 0.11 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.082 0.05 DBMET02818 0.108 0.031 DBMET02824 | ||
| 0.141 | 0.061 | 0.305 | c-Src kinase inhibitor | 0.305 0.017 DBMET00863 0.144 0.058 DBMET00864 0.144 0.058 DBMET02815 0.124 0.072 DBMET02816 0.13 0.068 DBMET02817 0.192 0.037 DBMET02818 0.109 0.083 DBMET02819 | DBMET00863 | |
| 0.122 | 0.045 | 0.138 | Carbonic anhydrase XV inhibitor | 0.138 0.036 DBMET02816 0.105 0.061 DBMET02818 | DBMET02816 | |
| 0.15 | 0.074 | 0.152 | Acetylcholine M1 receptor antagonist | 0.129 0.096 DBMET00863 0.152 0.072 DBMET02816 | DBMET02816 | |
| 0.106 | 0.032 | 0.106 | Inducible nitric-oxide synthase inhibitor | 0.076 0.07 DBMET02815 0.098 0.039 DBMET02816 0.091 0.046 DBMET02818 | ||
| 0.112 | 0.044 | 0.112 | Nitric-oxide synthase inhibitor | 0.105 0.052 DBMET02816 | ||
| 0.122 | 0.057 | 0.343 | Cyclin-dependent kinase 5 inhibitor | 0.252 0.015 DBMET02815 0.174 0.03 DBMET02816 0.212 0.02 DBMET02818 0.23 0.017 DBMET02820 0.343 0.007 DBMET02819 0.145 0.043 DBMET02821 0.119 0.059 DBMET02822 0.113 0.064 DBMET02823 | DBMET02819 | |
| 0.117 | 0.052 | 0.25 | Check point kinase 2 inhibitor | 0.25 0.01 DBMET02815 0.158 0.029 DBMET02816 0.192 0.019 DBMET02818 0.167 0.026 DBMET02820 0.232 0.012 DBMET02819 | DBMET02815 | |
| 0.121 | 0.057 | 0.221 | Cystathionine beta-synthase inhibitor | 0.129 0.052 DBMET02815 0.221 0.02 DBMET02816 0.121 0.057 DBMET02818 0.17 0.033 DBMET02822 | DBMET02816 | |
| 0.177 | 0.114 | 0.282 | 5 Hydroxytryptamine 3E antagonist | 0.176 0.118 DBMET00863 0.199 0.064 DBMET02815 0.282 0.007 DBMET02816 0.166 0.151 DBMET02820 0.181 0.104 DBMET02821 0.199 0.064 DBMET02824 | DBMET02816 | |
| 0.075 | 0.015 | 0.075 | Lysine-specific demethylase 1A inhibitor | 0.062 0.026 DBMET02816 | ||
| 0.184 | 0.125 | 0.476 | MAP-kinase-activated kinase 5 inhibitor | 0.176 0.138 DBMET00863 0.476 0.004 DBMET02815 0.355 0.01 DBMET02816 0.344 0.012 DBMET02818 0.17 0.148 DBMET02820 0.321 0.02 DBMET02819 | DBMET02815 | |
| 0.105 | 0.049 | 0.137 | CDK/cyclin complex inhibitor | 0.137 0.034 DBMET02815 0.086 0.063 DBMET02816 0.11 0.046 DBMET02818 0.084 0.064 DBMET02819 | DBMET02815 | |
| 0.112 | 0.055 | 0.149 | DOPA decarboxylase inhibitor | 0.103 0.07 DBMET02815 0.149 0.022 DBMET02816 0.102 0.072 DBMET02818 0.115 0.051 DBMET02822 | DBMET02816 | |
| 0.108 | 0.052 | 0.276 | GABA C receptor rho-1 antagonist | 0.107 0.053 DBMET00863 0.107 0.054 DBMET00864 0.108 0.052 DBMET02814 0.163 0.016 DBMET02815 0.276 0.004 DBMET02816 0.087 0.083 DBMET02817 0.143 0.024 DBMET02821 0.125 0.036 DBMET02822 0.106 0.054 DBMET02823 0.15 0.021 DBMET02824 | DBMET02816 | |
| 0.064 | 0.009 | 0.127 | Alpha 1d adrenoreceptor agonist | 0.06 0.011 DBMET00863 0.039 0.027 DBMET02814 0.105 0.004 DBMET02815 0.127 0.003 DBMET02816 0.079 0.005 DBMET02821 0.054 0.014 DBMET02822 0.086 0.005 DBMET02824 | DBMET02816 | |
| 0.145 | 0.092 | 0.203 | Heat shock protein 90 alpha antagonist | 0.198 0.05 DBMET00863 0.152 0.085 DBMET00864 0.19 0.056 DBMET02815 0.2 0.049 DBMET02816 0.203 0.048 DBMET02817 | DBMET02817 | |
| 0.141 | 0.088 | 0.295 | Cyclin-dependent kinase 8 inhibitor | 0.132 0.1 DBMET00863 0.166 0.064 DBMET02814 0.292 0.009 DBMET02815 0.249 0.016 DBMET02816 0.136 0.095 DBMET02818 0.135 0.095 DBMET02820 0.129 0.104 DBMET02819 0.186 0.046 DBMET02821 0.153 0.076 DBMET02822 0.133 0.099 DBMET02823 0.295 0.009 DBMET02824 | DBMET02824 | |
| 0.067 | 0.02 | 0.079 | Thromboxane synthase inhibitor | 0.051 0.045 DBMET00864 0.05 0.047 DBMET02815 0.061 0.026 DBMET02816 0.079 0.012 DBMET02817 0.06 0.027 DBMET02818 | DBMET02817 | |
| 0.05 | 0.005 | 0.05 | Thymidine phosphorylase inhibitor | 0.033 0.009 DBMET02815 0.035 0.008 DBMET02816 0.043 0.006 DBMET02818 0.027 0.016 DBMET02823 0.026 0.019 DBMET02824 | ||
| 0.066 | 0.023 | 0.125 | Factor IXa inhibitor | 0.059 0.028 DBMET00863 0.055 0.031 DBMET00864 0.125 0.005 DBMET02816 0.059 0.027 DBMET02820 0.078 0.017 DBMET02824 | DBMET02816 | |
| 0.108 | 0.066 | 0.292 | GABA C receptor antagonist | 0.108 0.067 DBMET00863 0.105 0.071 DBMET00864 0.185 0.016 DBMET02815 0.292 0.005 DBMET02816 0.131 0.042 DBMET02821 0.12 0.053 DBMET02822 0.099 0.08 DBMET02823 0.135 0.039 DBMET02824 | DBMET02816 | |
| 0.176 | 0.135 | 0.176 | Immunostimulant | |||
| 0.102 | 0.065 | 0.357 | GABA C receptor agonist | 0.129 0.044 DBMET00864 0.176 0.026 DBMET02815 0.357 0.006 DBMET02816 0.235 0.015 DBMET02817 0.099 0.068 DBMET02823 0.145 0.036 DBMET02824 | DBMET02816 | |
| 0.073 | 0.037 | 0.122 | Exportin-1 inhibitor | 0.07 0.044 DBMET00863 0.094 0.012 DBMET02815 0.122 0.004 DBMET02816 0.068 0.048 DBMET02818 0.115 0.005 DBMET02820 0.107 0.007 DBMET02819 0.068 0.048 DBMET02821 0.09 0.015 DBMET02824 | DBMET02816 | |
| 0.104 | 0.071 | 0.258 | 5 Hydroxytryptamine 3A agonist | 0.174 0.024 DBMET02814 0.25 0.005 DBMET02815 0.258 0.005 DBMET02816 0.11 0.065 DBMET02818 0.155 0.033 DBMET02821 0.141 0.04 DBMET02822 0.146 0.038 DBMET02824 | DBMET02816 | |
| 0.174 | 0.142 | 0.308 | Nitric-oxide synthase stimulant | 0.173 0.144 DBMET00863 0.215 0.067 DBMET02815 0.308 0.009 DBMET02816 0.182 0.123 DBMET02822 0.168 0.158 DBMET02824 | DBMET02816 | |
| 0.063 | 0.034 | 0.067 | Botulinum neurotoxin type A inhibitor | 0.065 0.031 DBMET02816 0.065 0.031 DBMET02818 0.063 0.033 DBMET02820 0.067 0.028 DBMET02819 | DBMET02819 | |
| 0.082 | 0.054 | 0.113 | Carbonic anhydrase VI inhibitor | 0.113 0.032 DBMET02816 0.071 0.07 DBMET02818 | DBMET02816 | |
| 0.074 | 0.05 | 0.116 | Glutamate decarboxylase inhibitor | 0.067 0.059 DBMET00864 0.076 0.048 DBMET02815 0.116 0.022 DBMET02816 0.096 0.032 DBMET02817 0.075 0.049 DBMET02818 | DBMET02816 | |
| 0.06 | 0.035 | 0.094 | Carbonic anhydrase VB inhibitor | 0.094 0.018 DBMET02816 | DBMET02816 | |
| 0.083 | 0.062 | 0.167 | mTOR complex 2 inhibitor | 0.082 0.064 DBMET00863 0.091 0.046 DBMET02814 0.11 0.024 DBMET02815 0.167 0.007 DBMET02816 0.13 0.013 DBMET02821 0.117 0.019 DBMET02822 0.112 0.022 DBMET02823 0.133 0.012 DBMET02824 | DBMET02816 | |
| 0.186 | 0.168 | 0.273 | MAP kinase kinase 3 inhibitor | 0.189 0.158 DBMET00863 0.252 0.03 DBMET02815 0.273 0.015 DBMET02816 0.183 0.179 DBMET02824 | DBMET02816 | |
| 0.034 | 0.018 | 0.034 | Endothelial nitric-oxide synthase inhibitor | |||
| 0.12 | 0.108 | 0.206 | Src kinase inhibitor | 0.206 0.051 DBMET00863 0.163 0.075 DBMET02815 0.162 0.075 DBMET02816 0.146 0.086 DBMET02818 | DBMET00863 | |
| 0.058 | 0.048 | 0.058 | CDK1/cyclin B inhibitor | 0.058 0.048 DBMET02816 | ||
| 0.104 | 0.096 | 0.361 | Alpha-N-acetylglucosaminidase inhibitor | 0.165 0.047 DBMET00864 0.189 0.037 DBMET02815 0.361 0.011 DBMET02816 0.113 0.085 DBMET02818 0.151 0.055 DBMET02820 0.151 0.055 DBMET02819 0.105 0.094 DBMET02821 0.195 0.035 DBMET02823 0.103 0.098 DBMET02824 | DBMET02816 | |
| 0.151 | 0.146 | 0.235 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.161 0.125 DBMET02815 0.235 0.05 DBMET02816 0.157 0.132 DBMET02818 0.18 0.093 DBMET02822 0.164 0.118 DBMET02823 0.169 0.109 DBMET02824 | DBMET02816 | |
| 0.061 | 0.058 | 0.091 | Carbonic anhydrase VA inhibitor | 0.091 0.029 DBMET02816 | DBMET02816 | |
| 0.129 | 0.126 | 0.177 | Ca2+-transporting ATPase inhibitor | 0.145 0.056 DBMET02815 0.177 0.009 DBMET02816 0.129 0.124 DBMET02817 0.138 0.083 DBMET02821 0.133 0.105 DBMET02822 0.136 0.089 DBMET02823 0.141 0.07 DBMET02824 | DBMET02816 | |
| 0.045 | 0.043 | 0.069 | Dopamine beta hydroxylase inhibitor | 0.067 0.01 DBMET00863 0.053 0.024 DBMET00864 0.069 0.008 DBMET02816 0.045 0.042 DBMET02822 0.053 0.025 DBMET02824 | DBMET02816 | |
| 0.083 | 0.081 | 0.23 | Cyclin-dependent kinase 1 inhibitor | 0.173 0.032 DBMET02815 0.23 0.021 DBMET02816 0.1 0.066 DBMET02821 0.097 0.068 DBMET02823 | DBMET02816 | |
| 0.092 | 0.092 | 0.258 | Protein kinase C gamma inhibitor | 0.258 0.006 DBMET02815 0.205 0.013 DBMET02816 0.098 0.08 DBMET02818 | DBMET02815 | |
| 0.05 | 0.052 | 0.094 | Fatty acid synthase inhibitor | 0.084 0.017 DBMET02815 0.094 0.013 DBMET02816 0.07 0.026 DBMET02820 | DBMET02816 | |
| 0.066 | 0.069 | 0.1 | GABA aminotransferase inhibitor | 0.079 0.048 DBMET02815 0.1 0.027 DBMET02816 0.077 0.05 DBMET02818 | DBMET02816 | |
| 0.025 | 0.029 | 0.075 | Nicotinic alpha3beta4 receptor agonist | 0.033 0.017 DBMET02815 0.075 0.003 DBMET02816 0.027 0.025 DBMET02824 | DBMET02816 | |
| 0.063 | 0.067 | 0.761 | Rho-associated kinase II inhibitor | 0.761 0.003 DBMET02815 0.444 0.004 DBMET02816 0.091 0.037 DBMET02818 0.092 0.037 DBMET02821 | DBMET02815 | |
| 0.014 | 0.019 | 0.068 | Alpha 2a adrenoreceptor agonist | 0.022 0.008 DBMET02815 0.068 0.003 DBMET02816 | DBMET02816 | |
| 0.048 | 0.053 | 0.134 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.051 0.047 DBMET00864 0.069 0.026 DBMET02815 0.134 0.01 DBMET02816 0.05 0.049 DBMET02821 0.084 0.019 DBMET02823 0.069 0.027 DBMET02824 | DBMET02816 | |
| 0.064 | 0.071 | 0.078 | Adenosine A3 receptor antagonist | 0.078 0.045 DBMET02816 0.071 0.056 DBMET02824 | DBMET02816 | |
| 0.051 | 0.058 | 0.076 | Cyclin A1 inhibitor | 0.076 0.017 DBMET02815 0.066 0.028 DBMET02816 0.061 0.037 DBMET02824 | DBMET02815 | |
| 0.064 | 0.074 | 0.219 | MAP kinase 10 inhibitor | 0.076 0.056 DBMET02814 0.113 0.027 DBMET02815 0.219 0.008 DBMET02816 0.108 0.03 DBMET02821 0.13 0.02 DBMET02824 | DBMET02816 | |
| 0.072 | 0.083 | 0.115 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.083 0.066 DBMET02814 0.115 0.035 DBMET02815 0.105 0.041 DBMET02816 0.08 0.071 DBMET02821 0.091 0.056 DBMET02823 0.106 0.041 DBMET02824 | DBMET02815 | |
| 0.059 | 0.07 | 0.284 | Porphobilinogen synthase inhibitor | 0.066 0.06 DBMET00863 0.13 0.025 DBMET00864 0.071 0.055 DBMET02814 0.152 0.02 DBMET02815 0.284 0.006 DBMET02816 0.16 0.018 DBMET02817 0.077 0.049 DBMET02820 0.071 0.055 DBMET02822 0.091 0.04 DBMET02823 0.066 0.06 DBMET02824 | DBMET02816 | |
| 0.056 | 0.069 | 0.13 | Histidine decarboxylase inhibitor | 0.13 0.023 DBMET02816 | DBMET02816 | |
| 0.052 | 0.066 | 0.086 | Carbonic anhydrase V inhibitor | 0.086 0.033 DBMET02816 | DBMET02816 | |
| 0.181 | 0.195 | 0.381 | 5 Hydroxytryptamine uptake stimulant | 0.244 0.087 DBMET02815 0.381 0.018 DBMET02816 | DBMET02816 | |
| 0.081 | 0.097 | 0.302 | Ferrochelatase inhibitor | 0.09 0.083 DBMET00863 0.149 0.038 DBMET00864 0.185 0.026 DBMET02814 0.196 0.023 DBMET02815 0.302 0.007 DBMET02816 0.133 0.046 DBMET02817 0.12 0.054 DBMET02818 0.092 0.081 DBMET02820 0.12 0.054 DBMET02819 0.133 0.046 DBMET02821 0.095 0.076 DBMET02823 0.103 0.067 DBMET02824 | DBMET02816 | |
| 0.114 | 0.131 | 0.154 | Thiol protease inhibitor | 0.135 0.087 DBMET00863 0.154 0.065 DBMET02816 0.13 0.097 DBMET02820 | DBMET02816 | |
| 0.132 | 0.149 | 0.256 | Succinate dehydrogenase inhibitor | 0.18 0.068 DBMET00864 0.201 0.048 DBMET02815 0.256 0.02 DBMET02816 0.185 0.063 DBMET02817 0.168 0.083 DBMET02818 0.16 0.095 DBMET02819 0.147 0.117 DBMET02822 0.147 0.118 DBMET02823 | DBMET02816 | |
| 0.063 | 0.081 | 0.071 | Platelet growth factor antagonist | 0.071 0.067 DBMET02816 | DBMET02816 | |
| 0.076 | 0.094 | 0.227 | Creatine kinase inhibitor | 0.09 0.072 DBMET00864 0.154 0.022 DBMET02815 0.227 0.007 DBMET02816 0.094 0.066 DBMET02821 0.173 0.016 DBMET02822 0.095 0.065 DBMET02823 0.118 0.042 DBMET02824 | DBMET02816 | |
| 0.041 | 0.06 | 0.131 | Aconitate hydratase inhibitor | 0.055 0.031 DBMET00864 0.06 0.026 DBMET02815 0.131 0.005 DBMET02816 0.086 0.012 DBMET02817 0.047 0.044 DBMET02823 | DBMET02816 | |
| 0.203 | 0.222 | 0.242 | DNA polymerase beta inhibitor | 0.225 0.207 DBMET02818 0.233 0.203 DBMET02820 0.238 0.2 DBMET02819 0.239 0.199 DBMET02821 0.242 0.198 DBMET02822 | DBMET02822 | |
| 0.003 | 0.023 | 0.008 | CC chemokine 6 receptor agonist | 0.008 0.003 DBMET02816 | DBMET02816 | |
| 0.073 | 0.093 | 0.106 | D-Ala-D-Ala ligase inhibitor | 0.085 0.056 DBMET02815 0.106 0.023 DBMET02816 | DBMET02816 | |
| 0.039 | 0.061 | 0.166 | Cyclin E inhibitor | 0.114 0.02 DBMET02815 0.166 0.008 DBMET02816 | DBMET02816 | |
| 0.111 | 0.134 | 0.243 | MAP3K9 inhibitor | 0.213 0.011 DBMET00863 0.186 0.022 DBMET00864 0.243 0.006 DBMET02815 0.125 0.104 DBMET02816 0.172 0.034 DBMET02817 0.226 0.008 DBMET02818 0.21 0.012 DBMET02819 | DBMET02815 | |
| 0.11 | 0.134 | 0.258 | Heat shock protein 90 antagonist | 0.13 0.098 DBMET00863 0.181 0.048 DBMET02815 0.162 0.062 DBMET02816 0.128 0.1 DBMET02817 0.171 0.055 DBMET02821 0.258 0.018 DBMET02822 0.122 0.111 DBMET02824 | DBMET02822 | |
| 0.053 | 0.078 | 0.717 | Rho-associated kinase inhibitor | 0.068 0.057 DBMET02814 0.717 0.004 DBMET02815 0.36 0.005 DBMET02816 0.156 0.018 DBMET02821 0.066 0.059 DBMET02822 0.116 0.028 DBMET02824 | DBMET02815 | |
| 0.032 | 0.056 | 0.159 | Cyclin E1 inhibitor | 0.09 0.022 DBMET02815 0.159 0.008 DBMET02816 | DBMET02816 | |
| 0.101 | 0.126 | 0.304 | Activin receptor-like kinase 2 inhibitor | 0.171 0.052 DBMET02814 0.304 0.012 DBMET02815 0.203 0.035 DBMET02816 0.128 0.087 DBMET02818 0.167 0.055 DBMET02821 0.147 0.069 DBMET02822 0.114 0.105 DBMET02823 0.18 0.047 DBMET02824 | DBMET02815 | |
| 0.079 | 0.104 | 0.281 | Cyclin-dependent kinase 2 inhibitor | 0.281 0.014 DBMET02815 0.211 0.022 DBMET02816 0.129 0.047 DBMET02818 0.108 0.062 DBMET02819 0.159 0.034 DBMET02821 0.1 0.069 DBMET02822 0.096 0.075 DBMET02823 | DBMET02815 | |
| 0.01 | 0.036 | 0.028 | Nicotinic acid receptor 1 antagonist | 0.02 0.009 DBMET02815 0.028 0.005 DBMET02816 0.021 0.008 DBMET02822 | DBMET02816 | |
| 0.082 | 0.109 | 0.176 | Adenylate kinase inhibitor | 0.106 0.058 DBMET00864 0.118 0.045 DBMET02815 0.176 0.019 DBMET02816 0.112 0.051 DBMET02817 0.097 0.073 DBMET02823 0.102 0.063 DBMET02824 | DBMET02816 | |
| 0.036 | 0.064 | 0.082 | Xanthine dehydrogenase inhibitor | 0.082 0.023 DBMET02815 0.075 0.028 DBMET02816 0.056 0.041 DBMET02822 0.05 0.046 DBMET02824 | DBMET02815 | |
| 0.049 | 0.078 | 0.098 | Syk tyrosine kinase inhibitor | 0.098 0.029 DBMET02815 0.062 0.057 DBMET02816 | DBMET02815 | |
| 0.1 | 0.13 | 0.173 | DNA repair enzyme inhibitor | 0.173 0.016 DBMET02815 0.157 0.026 DBMET02816 0.11 0.096 DBMET02818 0.108 0.101 DBMET02823 0.114 0.086 DBMET02824 | DBMET02815 | |
| 0.079 | 0.111 | 0.168 | Aurora-B kinase inhibitor | 0.097 0.086 DBMET02814 0.168 0.04 DBMET02815 0.125 0.061 DBMET02816 0.094 0.09 DBMET02824 | DBMET02815 | |
| 0.042 | 0.073 | 0.084 | Cyclin-dependent kinase 6 inhibitor | 0.062 0.038 DBMET02815 0.084 0.019 DBMET02816 0.068 0.033 DBMET02821 | DBMET02816 | |
| 0.027 | 0.059 | 0.068 | CDK5/p25 inhibitor | 0.068 0.012 DBMET02815 0.042 0.028 DBMET02816 0.047 0.023 DBMET02818 0.06 0.015 DBMET02819 | DBMET02815 | |
| 0.04 | 0.072 | 0.088 | Cyclin A inhibitor | 0.067 0.039 DBMET02815 0.088 0.028 DBMET02816 0.06 0.044 DBMET02824 | DBMET02816 | |
| 0.036 | 0.068 | 0.065 | Adenosine A1 receptor antagonist | 0.065 0.036 DBMET02823 0.059 0.04 DBMET02824 | DBMET02823 | |
| 0.094 | 0.127 | 0.157 | Alkaline phosphatase inhibitor | 0.142 0.066 DBMET02815 0.138 0.069 DBMET02816 0.121 0.085 DBMET02821 0.157 0.055 DBMET02822 | DBMET02822 | |
| 0.014 | 0.047 | 0.047 | Cyclin E2 inhibitor | 0.035 0.015 DBMET02815 0.047 0.01 DBMET02816 | DBMET02816 | |
| 0.017 | 0.05 | 0.04 | Phosphodiesterase 9A inhibitor | 0.031 0.008 DBMET02814 0.024 0.018 DBMET02815 0.04 0.005 DBMET02816 0.031 0.008 DBMET02821 0.029 0.01 DBMET02824 | DBMET02816 | |
| 0.053 | 0.087 | 0.131 | Glutamate (mGluR7) antagonist | 0.099 0.011 DBMET02814 0.097 0.012 DBMET02815 0.131 0.004 DBMET02816 0.08 0.028 DBMET02821 0.073 0.038 DBMET02822 0.067 0.049 DBMET02823 0.083 0.024 DBMET02824 | DBMET02816 | |
| 0.113 | 0.147 | 0.315 | LIM domain kinase 1 inhibitor | 0.139 0.11 DBMET02814 0.315 0.018 DBMET02815 0.234 0.046 DBMET02816 0.155 0.092 DBMET02818 0.127 0.125 DBMET02819 0.129 0.122 DBMET02821 0.184 0.071 DBMET02824 | DBMET02815 | |
| 0.071 | 0.105 | 0.13 | Granulocyte macrophage colony stimulating factor agonist | 0.085 0.061 DBMET02815 0.13 0.01 DBMET02816 0.084 0.064 DBMET02823 | DBMET02816 | |
| 0.009 | 0.044 | 0.019 | Cyclin D2 inhibitor | 0.019 0.004 DBMET02816 | DBMET02816 | |
| 0.039 | 0.075 | 0.088 | Adenosine A2a receptor antagonist | 0.057 0.047 DBMET02816 0.07 0.036 DBMET02821 0.053 0.052 DBMET02822 0.088 0.028 DBMET02823 0.079 0.032 DBMET02824 | DBMET02823 | |
| 0.086 | 0.122 | 0.223 | CDK3/cyclin E inhibitor | 0.223 0.004 DBMET02815 0.179 0.012 DBMET02816 0.118 0.059 DBMET02820 | DBMET02815 | |
| 0.033 | 0.07 | 0.062 | Histamine H1 receptor agonist | 0.062 0.007 DBMET02816 0.043 0.031 DBMET02824 | DBMET02816 | |
| 0.012 | 0.051 | 0.018 | Antibiotic Anthracycline-like | 0.018 0.015 DBMET02816 | DBMET02816 | |
| 0.007 | 0.046 | 0.016 | CD80 antagonist | 0.016 0.004 DBMET02815 0.013 0.005 DBMET02816 | DBMET02815 | |
| 0.07 | 0.111 | 0.233 | UDP-glucose 4-epimerase inhibitor | 0.133 0.036 DBMET02815 0.233 0.014 DBMET02816 0.121 0.042 DBMET02823 | DBMET02816 | |
| 0.032 | 0.074 | 0.064 | mTOR inhibitor | 0.064 0.026 DBMET02816 0.047 0.043 DBMET02821 0.054 0.034 DBMET02824 | DBMET02816 | |
| 0.091 | 0.133 | 0.639 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.18 0.06 DBMET02814 0.639 0.004 DBMET02815 0.357 0.014 DBMET02816 0.351 0.015 DBMET02818 0.112 0.108 DBMET02820 0.343 0.016 DBMET02819 0.17 0.065 DBMET02821 0.146 0.08 DBMET02822 0.234 0.04 DBMET02824 | DBMET02815 | |
| 0.023 | 0.067 | 0.05 | Vascular adhesion protein 1 inhibitor | 0.039 0.026 DBMET02815 0.05 0.015 DBMET02816 | DBMET02816 | |
| 0.028 | 0.072 | 0.073 | Geranyltranstransferase inhibitor | 0.042 0.033 DBMET02815 0.073 0.006 DBMET02816 0.04 0.037 DBMET02824 | DBMET02816 | |
| 0.03 | 0.075 | 0.041 | Dihydrofolate reductase inhibitor | 0.041 0.036 DBMET02816 | DBMET02816 | |
| 0.039 | 0.084 | 0.069 | Adenosine A2 receptor antagonist | 0.059 0.05 DBMET02816 0.058 0.051 DBMET02821 0.069 0.041 DBMET02823 0.069 0.04 DBMET02824 | DBMET02824 | |
| 0.025 | 0.07 | 0.055 | Angiotensin AT1 receptor antagonist | 0.043 0.028 DBMET02814 0.038 0.037 DBMET02815 0.046 0.023 DBMET02816 0.055 0.011 DBMET02821 0.055 0.011 DBMET02823 | DBMET02823 | |
| 0.052 | 0.098 | 0.225 | CYP2A6 inhibitor | 0.122 0.026 DBMET02815 0.225 0.005 DBMET02816 0.08 0.049 DBMET02821 0.081 0.048 DBMET02824 | DBMET02816 | |
| 0.006 | 0.052 | 0.018 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.018 0.005 DBMET02816 | DBMET02816 | |
| 0.038 | 0.086 | 0.094 | Cyclin A2 inhibitor | 0.069 0.039 DBMET02815 0.094 0.027 DBMET02816 0.067 0.041 DBMET02824 | DBMET02816 | |
| 0.023 | 0.071 | 0.043 | ATR kinase inhibitor | 0.037 0.016 DBMET02815 0.043 0.01 DBMET02816 0.032 0.024 DBMET02821 0.031 0.026 DBMET02824 | DBMET02816 | |
| 0.027 | 0.076 | 0.042 | Adenosine uptake inhibitor | 0.042 0.01 DBMET02816 | DBMET02816 | |
| 0.021 | 0.071 | 0.042 | Angiotensin II receptor antagonist | 0.035 0.022 DBMET02816 0.041 0.013 DBMET02821 0.042 0.012 DBMET02823 | DBMET02823 | |
| 0.013 | 0.064 | 0.056 | Nicotinic alpha4beta2 receptor agonist | 0.056 0.004 DBMET02816 | DBMET02816 | |
| 0.018 | 0.07 | 0.035 | Complement factor 1s inhibitor | 0.035 0.005 DBMET02816 0.027 0.013 DBMET02824 | DBMET02816 | |
| 0.011 | 0.063 | 0.05 | Kynurenine 3 monooxygenase inhibitor | 0.03 0.016 DBMET00864 0.05 0.007 DBMET02816 0.047 0.007 DBMET02817 | DBMET02816 | |
| 0.007 | 0.059 | 0.041 | Steroid 17-alpha-hydroxylase/17,20 lyase inhibitor | 0.041 0.007 DBMET02816 | DBMET02816 | |
| 0.034 | 0.086 | 0.06 | Topoisomerase II beta inhibitor | 0.06 0.022 DBMET02816 | DBMET02816 | |
| 0.024 | 0.077 | 0.08 | MAP3K5 inhibitor | 0.064 0.005 DBMET02814 0.056 0.007 DBMET02815 0.064 0.005 DBMET02816 0.064 0.005 DBMET02821 0.053 0.01 DBMET02822 0.056 0.008 DBMET02823 0.08 0.003 DBMET02824 | DBMET02824 | |
| 0.023 | 0.075 | 0.051 | Glutamate (mGluR4) agonist | 0.046 0.012 DBMET02815 0.051 0.01 DBMET02816 0.033 0.025 DBMET02817 | DBMET02816 | |
| 0.013 | 0.066 | 0.039 | Phosphodiesterase IX inhibitor | 0.03 0.009 DBMET02814 0.021 0.02 DBMET02815 0.039 0.005 DBMET02816 0.03 0.009 DBMET02821 0.027 0.012 DBMET02824 | DBMET02816 | |
| 0.158 | 0.211 | 0.199 | Neuropeptide Y2 antagonist | 0.199 0.12 DBMET02816 0.195 0.129 DBMET02818 | DBMET02816 | |
| 0.069 | 0.123 | 0.193 | Protein kinase (CK2) alpha inhibitor | 0.092 0.084 DBMET02814 0.193 0.026 DBMET02815 0.131 0.055 DBMET02816 0.11 0.069 DBMET02818 0.111 0.068 DBMET02819 0.16 0.036 DBMET02821 0.171 0.032 DBMET02822 0.167 0.033 DBMET02824 | DBMET02815 | |
| 0.032 | 0.087 | 0.071 | Glucose-6-phosphate isomerase inhibitor | 0.071 0.012 DBMET02816 0.047 0.035 DBMET02817 0.049 0.031 DBMET02823 | DBMET02816 | |
| 0.029 | 0.084 | 0.054 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.054 0.011 DBMET02816 | DBMET02816 | |
| 0.01 | 0.065 | 0.076 | Methionyl aminopeptidase 2 inhibitor | 0.076 0.004 DBMET02815 0.051 0.006 DBMET02816 | DBMET02815 | |
| 0.109 | 0.164 | 0.403 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.165 0.106 DBMET02814 0.325 0.022 DBMET02815 0.403 0.01 DBMET02816 0.196 0.08 DBMET02821 0.174 0.098 DBMET02822 0.244 0.048 DBMET02824 | DBMET02816 | |
| 0.05 | 0.105 | 0.064 | Kallikrein 7 inhibitor | 0.064 0.042 DBMET02816 | DBMET02816 | |
| 0.06 | 0.117 | 0.234 | Protein kinase C delta inhibitor | 0.234 0.005 DBMET02815 0.162 0.017 DBMET02816 | DBMET02815 | |
| 0.066 | 0.125 | 0.102 | Cyclin-dependent kinase 9 inhibitor | 0.099 0.064 DBMET02815 0.102 0.061 DBMET02816 0.086 0.082 DBMET02824 | DBMET02816 | |
| 0.034 | 0.093 | 0.104 | Carbamoyl phosphate synthetase inhibitor | 0.058 0.045 DBMET02815 0.104 0.019 DBMET02816 0.077 0.03 DBMET02817 | DBMET02816 | |
| 0.064 | 0.123 | 0.142 | NADH dehydrogenase inhibitor | 0.087 0.06 DBMET02815 0.142 0.019 DBMET02816 0.095 0.05 DBMET02823 0.087 0.061 DBMET02824 | DBMET02816 | |
| 0.037 | 0.096 | 0.118 | Cyclin B1 inhibitor | 0.118 0.008 DBMET02816 | DBMET02816 | |
| 0.046 | 0.107 | 0.171 | Leucine-rich repeat kinase 2 inhibitor | 0.121 0.03 DBMET02814 0.133 0.026 DBMET02815 0.127 0.028 DBMET02816 0.149 0.02 DBMET02821 0.098 0.044 DBMET02822 0.093 0.047 DBMET02823 0.171 0.014 DBMET02824 | DBMET02824 | |
| 0.03 | 0.092 | 0.534 | GABA A receptor antagonist | 0.266 0.005 DBMET02814 0.047 0.046 DBMET02815 0.122 0.012 DBMET02816 0.047 0.046 DBMET02820 0.509 0.003 DBMET02821 0.42 0.004 DBMET02822 0.41 0.004 DBMET02823 0.534 0.003 DBMET02824 | DBMET02824 | |
| 0.145 | 0.209 | 0.28 | Lipoxygenase inhibitor | 0.28 0.081 DBMET00864 0.204 0.136 DBMET02817 | DBMET00864 | |
| 0.092 | 0.157 | 0.115 | Diuretic | 0.114 0.112 DBMET02816 0.115 0.111 DBMET02818 | DBMET02818 | |
| 0.046 | 0.111 | 0.172 | Phosphodiesterase 1C inhibitor | 0.131 0.005 DBMET02814 0.063 0.042 DBMET02815 0.112 0.008 DBMET02816 0.172 0.004 DBMET02821 0.151 0.005 DBMET02822 0.127 0.006 DBMET02823 0.113 0.008 DBMET02824 | DBMET02821 | |
| 0.061 | 0.129 | 0.162 | Falcipain 3 inhibitor | 0.118 0.055 DBMET02815 0.162 0.031 DBMET02816 0.112 0.059 DBMET02820 0.095 0.075 DBMET02819 0.093 0.078 DBMET02824 | DBMET02816 | |
| 0.021 | 0.088 | 0.069 | Dopamine D5 agonist | 0.069 0.009 DBMET02816 0.037 0.032 DBMET02822 | DBMET02816 | |
| 0.007 | 0.074 | 0.018 | Thromboxane A2 agonist | 0.018 0.008 DBMET02816 | DBMET02816 | |
| 0.032 | 0.1 | 0.124 | Biliverdin reductase inhibitor | 0.069 0.033 DBMET02815 0.124 0.013 DBMET02816 | DBMET02816 | |
| 0.049 | 0.117 | 0.074 | Transcription factor RelA inhibitor | 0.061 0.051 DBMET02815 0.074 0.023 DBMET02816 | DBMET02816 | |
| 0.041 | 0.11 | 0.139 | Nav1.7 sodium channel blocker | 0.097 0.024 DBMET02815 0.139 0.013 DBMET02816 | DBMET02816 | |
| 0.004 | 0.073 | 0.014 | Egl nine homolog 3 inhibitor | 0.014 0.006 DBMET02815 0.013 0.007 DBMET02816 | DBMET02815 | |
| 0.038 | 0.108 | 0.152 | Phenylalanine 4-hydroxylase inhibitor | 0.069 0.047 DBMET02815 0.152 0.012 DBMET02816 | DBMET02816 | |
| 0.013 | 0.084 | 0.037 | Nicotinic acid receptor 2 antagonist | 0.037 0.007 DBMET02815 0.033 0.009 DBMET02816 | DBMET02815 | |
| 0.029 | 0.1 | 0.529 | GABA receptor antagonist | 0.26 0.005 DBMET02814 0.123 0.012 DBMET02816 0.503 0.003 DBMET02821 0.425 0.004 DBMET02822 0.424 0.004 DBMET02823 0.529 0.003 DBMET02824 | DBMET02824 | |
| 0.041 | 0.113 | 0.137 | CDK2/cyclin E2 inhibitor | 0.137 0.019 DBMET02815 0.092 0.031 DBMET02816 | DBMET02815 | |
| 0.043 | 0.115 | 0.239 | Rho-associated kinase I inhibitor | 0.239 0.006 DBMET02815 0.107 0.027 DBMET02816 | DBMET02815 | |
| 0.005 | 0.08 | 0.018 | Carbonic anhydrase X inhibitor | 0.018 0.01 DBMET02816 | DBMET02816 | |
| 0.005 | 0.08 | 0.018 | Carbonic anhydrase VIII inhibitor | 0.018 0.01 DBMET02816 | DBMET02816 | |
| 0.075 | 0.151 | 0.241 | Activin receptor-like kinase 4 inhibitor | 0.138 0.035 DBMET02814 0.201 0.014 DBMET02815 0.241 0.008 DBMET02816 0.144 0.032 DBMET02821 0.109 0.068 DBMET02822 0.102 0.081 DBMET02823 0.175 0.019 DBMET02824 | DBMET02816 | |
| 0.034 | 0.11 | 0.1 | Cyclin D1 inhibitor | 0.078 0.02 DBMET02815 0.1 0.008 DBMET02816 0.069 0.03 DBMET02820 | DBMET02816 | |
| 0.054 | 0.13 | 0.274 | Tyrosine-protein kinase receptor FLT3 inhibitor | 0.152 0.052 DBMET02815 0.112 0.072 DBMET02816 0.274 0.023 DBMET02824 | DBMET02824 | |
| 0.028 | 0.105 | 0.061 | Transforming growth factor beta 1 antagonist | 0.052 0.032 DBMET02815 0.061 0.025 DBMET02816 0.047 0.037 DBMET02821 0.05 0.033 DBMET02824 | DBMET02816 | |
| 0.057 | 0.134 | 0.168 | Protein kinase C mu inhibitor | 0.159 0.022 DBMET02815 0.168 0.019 DBMET02816 | DBMET02816 | |
| 0.042 | 0.119 | 0.094 | Fibroblast growth factor 3 antagonist | 0.094 0.036 DBMET02815 0.094 0.037 DBMET02816 0.07 0.064 DBMET02824 | DBMET02816 | |
| 0.04 | 0.117 | 0.163 | Benzodiazepine agonist | 0.163 0.006 DBMET02814 0.067 0.055 DBMET02815 0.115 0.018 DBMET02816 0.15 0.008 DBMET02821 0.085 0.035 DBMET02822 0.104 0.023 DBMET02823 0.15 0.008 DBMET02824 | DBMET02814 | |
| 0.024 | 0.103 | 0.062 | 5 Hydroxytryptamine 2B agonist | 0.062 0.008 DBMET02816 | DBMET02816 | |
| 0.007 | 0.085 | 0.027 | Nicotinic alpha4 receptor agonist | 0.027 0.005 DBMET02816 | DBMET02816 | |
| 0.034 | 0.113 | 0.091 | 5 Hydroxytryptamine 3A antagonist | 0.067 0.046 DBMET02815 0.091 0.022 DBMET02816 | DBMET02816 | |
| 0.111 | 0.19 | 0.199 | MAP kinase kinase 4 inhibitor | 0.128 0.12 DBMET02814 0.179 0.025 DBMET02815 0.199 0.014 DBMET02816 0.16 0.044 DBMET02821 0.187 0.02 DBMET02822 0.14 0.084 DBMET02823 0.162 0.043 DBMET02824 | DBMET02816 | |
| 0.007 | 0.086 | 0.029 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.029 0.018 DBMET02816 | DBMET02816 | |
| 0.051 | 0.132 | 0.13 | MAP-kinase-activated kinase inhibitor | 0.075 0.069 DBMET00863 0.13 0.021 DBMET02815 0.103 0.036 DBMET02816 | DBMET02815 | |
| 0.007 | 0.089 | 0.016 | Telomerase stimulant | 0.016 0.014 DBMET02816 | DBMET02816 | |
| 0.117 | 0.199 | 0.361 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.361 0.022 DBMET02815 0.327 0.031 DBMET02816 0.151 0.143 DBMET02819 | DBMET02815 | |
| 0.059 | 0.14 | 0.173 | Triose-phosphate isomerase inhibitor | 0.098 0.05 DBMET02815 0.173 0.015 DBMET02816 0.091 0.059 DBMET02817 0.095 0.053 DBMET02823 | DBMET02816 | |
| 0.03 | 0.112 | 0.058 | Alpha-mannosidase inhibitor | 0.058 0.029 DBMET02816 | DBMET02816 | |
| 0.024 | 0.105 | 0.048 | Glutamate (mGluR8) agonist | 0.048 0.013 DBMET02816 | DBMET02816 | |
| 0.014 | 0.096 | 0.047 | Fumarate hydratase inhibitor | 0.047 0.015 DBMET02816 | DBMET02816 | |
| 0.009 | 0.091 | 0.027 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.027 0.019 DBMET02816 | DBMET02816 | |
| 0.018 | 0.101 | 0.037 | Glucosylceramidase stimulant | 0.03 0.012 DBMET02814 0.037 0.005 DBMET02816 0.031 0.01 DBMET02821 0.029 0.015 DBMET02824 | DBMET02816 | |
| 0.015 | 0.099 | 0.033 | 5 Hydroxytryptamine 6 agonist | 0.033 0.013 DBMET02816 | DBMET02816 | |
| 0.063 | 0.148 | 0.169 | Protein kinase C zeta inhibitor | 0.169 0.016 DBMET02815 0.146 0.021 DBMET02816 0.096 0.056 DBMET02822 | DBMET02815 | |
| 0.055 | 0.14 | 0.102 | GABA B receptor agonist | 0.074 0.056 DBMET00864 0.102 0.015 DBMET02816 0.079 0.045 DBMET02817 0.071 0.064 DBMET02821 0.081 0.039 DBMET02822 0.072 0.061 DBMET02823 | DBMET02816 | |
| 0.056 | 0.141 | 0.189 | Prolactin inhibitor | 0.135 0.029 DBMET02815 0.189 0.011 DBMET02816 | DBMET02816 | |
| 0.015 | 0.102 | 0.033 | Purinergic P2Y15 antagonist | 0.033 0.013 DBMET02816 | DBMET02816 | |
| 0.003 | 0.091 | 0.012 | Lysophosphatidic acid receptor 3 agonist | 0.012 0.011 DBMET02816 | DBMET02816 | |
| 0.067 | 0.155 | 0.105 | Acetylcholine antagonist | 0.105 0.085 DBMET02816 | DBMET02816 | |
| 0.021 | 0.109 | 0.041 | Protein kinase (CK2) beta inhibitor | 0.031 0.029 DBMET02815 0.041 0.011 DBMET02816 | DBMET02816 | |
| 0.132 | 0.22 | 0.561 | 5 Hydroxytryptamine release stimulant | 0.176 0.145 DBMET02815 0.561 0.019 DBMET02816 | DBMET02816 | |
| 0.055 | 0.143 | 0.116 | Granulocyte macrophage colony stimulating factor antagonist | 0.095 0.078 DBMET02815 0.116 0.056 DBMET02816 | DBMET02816 | |
| 0.021 | 0.11 | 0.064 | Histamine H2 receptor agonist | 0.05 0.022 DBMET02815 0.064 0.013 DBMET02816 | DBMET02816 | |
| 0.076 | 0.165 | 0.194 | Toll-Like receptor 9 antagonist | 0.194 0.038 DBMET02816 | DBMET02816 | |
| 0.03 | 0.12 | 0.125 | Phosphofructokinase-1 inhibitor | 0.125 0.024 DBMET02816 0.073 0.046 DBMET02817 0.066 0.051 DBMET02823 | DBMET02816 | |
| 0.026 | 0.116 | 0.095 | Argininosuccinate synthase inhibitor | 0.095 0.02 DBMET02816 | DBMET02816 | |
| 0.063 | 0.154 | 0.102 | Estrogen-related receptor beta agonist | 0.081 0.062 DBMET02815 0.102 0.022 DBMET02816 0.081 0.063 DBMET02822 | DBMET02816 | |
| 0.024 | 0.115 | 0.088 | Acyl-CoA dehydrogenase inhibitor | 0.088 0.019 DBMET02816 | DBMET02816 | |
| 0.021 | 0.113 | 0.049 | Tryptophan 5 hydroxylase inhibitor | 0.049 0.005 DBMET02816 | DBMET02816 | |
| 0.029 | 0.121 | 0.05 | Histamine H4 receptor antagonist | 0.05 0.03 DBMET02816 | DBMET02816 | |
| 0.02 | 0.113 | 0.047 | Mannosidase inhibitor | 0.047 0.029 DBMET02816 | DBMET02816 | |
| 0.028 | 0.121 | 0.104 | 5 Hydroxytryptamine 2A agonist | 0.104 0.013 DBMET02816 0.059 0.048 DBMET02821 0.056 0.052 DBMET02822 | DBMET02816 | |
| 0.089 | 0.182 | 0.238 | Mannose-6-phosphate isomerase inhibitor | 0.126 0.091 DBMET02814 0.2 0.03 DBMET02815 0.238 0.015 DBMET02816 0.121 0.1 DBMET02818 0.134 0.08 DBMET02821 0.122 0.098 DBMET02822 0.121 0.099 DBMET02823 | DBMET02816 | |
| 0.067 | 0.16 | 0.107 | Cholinergic antagonist | 0.107 0.086 DBMET02816 | DBMET02816 | |
| 0.012 | 0.105 | 0.046 | Potassium channel small-conductance Ca-activated activator | 0.046 0.012 DBMET02816 0.031 0.022 DBMET02824 | DBMET02816 | |
| 0.015 | 0.109 | 0.035 | DNA gyrase subunit B inhibitor | 0.035 0.031 DBMET02815 | DBMET02815 | |
| 0.023 | 0.117 | 0.085 | Glutamate (mGluR group III) agonist | 0.069 0.015 DBMET02815 0.085 0.012 DBMET02816 0.041 0.032 DBMET02824 | DBMET02816 | |
| 0.036 | 0.13 | 0.117 | 5 Hydroxytryptamine 3 agonist | 0.072 0.033 DBMET02815 0.117 0.009 DBMET02816 | DBMET02816 | |
| 0.009 | 0.103 | 0.049 | Glutamate (mGluR1a) agonist | 0.049 0.005 DBMET02816 | DBMET02816 | |
| 0.071 | 0.165 | 0.486 | Phosphodiesterase inhibitor | 0.244 0.024 DBMET02814 0.179 0.042 DBMET02815 0.297 0.015 DBMET02816 0.486 0.005 DBMET02821 0.354 0.01 DBMET02822 0.277 0.018 DBMET02823 0.266 0.019 DBMET02824 | DBMET02821 | |
| 0.102 | 0.197 | 0.185 | MAP kinase 3 inhibitor | 0.185 0.031 DBMET02815 0.165 0.048 DBMET02816 0.125 0.119 DBMET02824 | DBMET02815 | |
| 0.039 | 0.135 | 0.106 | Aminopeptidase I inhibitor | 0.106 0.025 DBMET02816 | DBMET02816 | |
| 0.026 | 0.123 | 0.062 | GABA B receptor antagonist | 0.061 0.012 DBMET02816 0.062 0.011 DBMET02821 0.05 0.02 DBMET02822 0.04 0.035 DBMET02823 | DBMET02821 | |
| 0.191 | 0.288 | 0.522 | MAP kinase kinase 6 inhibitor | 0.32 0.117 DBMET02814 0.449 0.035 DBMET02815 0.522 0.014 DBMET02816 0.306 0.13 DBMET02821 0.226 0.223 DBMET02822 0.375 0.074 DBMET02824 | DBMET02816 | |
| 0.045 | 0.143 | 0.156 | Protein kinase (CK2) inhibitor | 0.114 0.052 DBMET02814 0.156 0.03 DBMET02815 0.114 0.052 DBMET02816 0.128 0.044 DBMET02821 0.138 0.038 DBMET02822 0.154 0.031 DBMET02824 | DBMET02815 | |
| 0.041 | 0.139 | 0.11 | MAP-kinase-activated kinase 2 inhibitor | 0.11 0.024 DBMET02815 0.09 0.035 DBMET02816 | DBMET02815 | |
| 0.043 | 0.141 | 0.11 | Glutamate dehydrogenase inhibitor | 0.11 0.026 DBMET02816 0.078 0.047 DBMET02817 | DBMET02816 | |
| 0.062 | 0.16 | 0.227 | Glycogen synthase kinase-3 alpha inhibitor | 0.13 0.078 DBMET02814 0.227 0.034 DBMET02815 0.196 0.042 DBMET02816 0.163 0.057 DBMET02821 0.156 0.062 DBMET02822 0.118 0.086 DBMET02823 0.171 0.052 DBMET02824 | DBMET02815 | |
| 0.087 | 0.186 | 0.482 | Protein kinase (CK1) gamma 3 inhibitor | 0.482 0.005 DBMET02815 0.252 0.027 DBMET02816 0.221 0.037 DBMET02818 0.202 0.046 DBMET02819 0.18 0.06 DBMET02824 | DBMET02815 | |
| 0.02 | 0.119 | 0.045 | Fructose-1,6-bisphosphatase inhibitor | 0.045 0.031 DBMET02816 | DBMET02816 | |
| 0.028 | 0.128 | 0.044 | CF transmembrane conductance regulator antagonist | 0.044 0.015 DBMET02816 0.04 0.025 DBMET02823 | DBMET02816 | |
| 0.003 | 0.104 | 0.011 | Imidazoline I2 receptor antagonist | 0.011 0.008 DBMET02816 | DBMET02816 | |
| 0.008 | 0.11 | 0.019 | CC chemokine 9 receptor antagonist | 0.019 0.009 DBMET02816 | DBMET02816 | |
| 0.034 | 0.137 | 0.068 | Dihydroorotate oxidase inhibitor | 0.061 0.027 DBMET02815 0.068 0.019 DBMET02816 | DBMET02816 | |
| 0.007 | 0.11 | 0.053 | Acetyl-CoA carboxylase 1 inhibitor | 0.053 0.005 DBMET02815 0.024 0.01 DBMET02816 | DBMET02815 | |
| 0.005 | 0.109 | 0.019 | Cyclin T1 inhibitor | 0.019 0.011 DBMET02816 | DBMET02816 | |
| 0.05 | 0.154 | 0.144 | Pim-3 kinase inhibitor | 0.11 0.037 DBMET02814 0.144 0.02 DBMET02815 0.114 0.035 DBMET02816 0.1 0.046 DBMET02821 0.081 0.076 DBMET02822 0.132 0.025 DBMET02824 | DBMET02815 | |
| 0.038 | 0.142 | 0.107 | Aryl hydrocarbon receptor antagonist | 0.065 0.044 DBMET02815 0.107 0.011 DBMET02816 0.086 0.022 DBMET02821 0.075 0.032 DBMET02822 0.06 0.054 DBMET02823 0.078 0.029 DBMET02824 | DBMET02816 | |
| 0.021 | 0.125 | 0.057 | Protein kinase (CK1) epsilon inhibitor | 0.057 0.009 DBMET02816 | DBMET02816 | |
| 0.004 | 0.108 | 0.02 | Egl nine homolog 1 inhibitor | 0.02 0.005 DBMET02816 | DBMET02816 | |
| 0.012 | 0.116 | 0.026 | Lysophosphatidic acid receptor 1 agonist | 0.026 0.016 DBMET02816 | DBMET02816 | |
| 0.056 | 0.162 | 0.092 | MAP kinase kinase 7 inhibitor | 0.078 0.053 DBMET02815 0.092 0.022 DBMET02816 0.088 0.028 DBMET02822 | DBMET02816 | |
| 0.029 | 0.135 | 0.195 | CDC7 inhibitor | 0.087 0.031 DBMET02814 0.195 0.005 DBMET02815 0.1 0.023 DBMET02816 0.061 0.056 DBMET02821 0.074 0.04 DBMET02824 | DBMET02815 | |
| 0.052 | 0.159 | 0.187 | Protein kinase (CK1) delta inhibitor | 0.166 0.044 DBMET02815 0.187 0.033 DBMET02816 0.164 0.045 DBMET02821 0.098 0.094 DBMET02823 0.105 0.087 DBMET02824 | DBMET02816 | |
| 0.016 | 0.123 | 0.034 | Estrogen-related receptor gamma antagonist | 0.034 0.01 DBMET02816 | DBMET02816 | |
| 0.045 | 0.153 | 0.09 | Glutamate (mGluR6) antagonist | 0.09 0.016 DBMET02816 | DBMET02816 | |
| 0.021 | 0.13 | 0.063 | Nerve growth factor antagonist | 0.044 0.027 DBMET02815 0.063 0.008 DBMET02816 | DBMET02816 | |
| 0.033 | 0.143 | 0.114 | Protein kinase C beta inhibitor | 0.114 0.009 DBMET02815 0.094 0.017 DBMET02816 0.064 0.06 DBMET02818 | DBMET02815 | |
| 0.009 | 0.12 | 0.023 | Alpha 2b adrenoreceptor agonist | 0.023 0.007 DBMET02816 | DBMET02816 | |
| 0.097 | 0.209 | 0.274 | I kappa B kinase epsilon inhibitor | 0.274 0.026 DBMET02815 0.261 0.032 DBMET02816 0.184 0.085 DBMET02821 0.166 0.103 DBMET02822 0.198 0.073 DBMET02824 | DBMET02815 | |
| 0.017 | 0.129 | 0.035 | Hedgehog signaling activator | 0.035 0.007 DBMET02816 | DBMET02816 | |
| 0.016 | 0.129 | 0.06 | Ornithine carbamoyltransferase inhibitor | 0.06 0.032 DBMET02816 | DBMET02816 | |
| 0.022 | 0.135 | 0.111 | Cyclin B2 inhibitor | 0.111 0.007 DBMET02816 | DBMET02816 | |
| 0.025 | 0.139 | 0.095 | Pim-2 kinase inhibitor | 0.058 0.033 DBMET02814 0.054 0.038 DBMET02815 0.061 0.03 DBMET02816 0.052 0.042 DBMET02821 0.095 0.016 DBMET02824 | DBMET02824 | |
| 0.056 | 0.17 | 0.13 | Anabolic | 0.103 0.058 DBMET02815 0.13 0.031 DBMET02816 0.093 0.073 DBMET02822 | DBMET02816 | |
| 0.009 | 0.124 | 0.022 | Isoleucine-tRNA ligase inhibitor | 0.022 0.018 DBMET02816 | DBMET02816 | |
| 0.007 | 0.123 | 0.045 | Uridine phosphorylase inhibitor | 0.045 0.01 DBMET02816 | DBMET02816 | |
| 0.045 | 0.162 | 0.103 | Urease inhibitor | 0.103 0.064 DBMET02816 | DBMET02816 | |
| 0.033 | 0.15 | 0.096 | Purinergic P2X1 antagonist | 0.096 0.018 DBMET02816 | DBMET02816 | |
| 0.066 | 0.183 | 0.222 | Sodium channel (voltage-gated) blocker | 0.156 0.05 DBMET02815 0.222 0.022 DBMET02816 | DBMET02816 | |
| 0.032 | 0.149 | 0.794 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.794 0.003 DBMET02815 0.131 0.024 DBMET02816 0.367 0.005 DBMET02818 0.311 0.007 DBMET02819 | DBMET02815 | |
| 0.03 | 0.149 | 0.053 | Heme oxygenase inhibitor | 0.053 0.01 DBMET02816 0.041 0.039 DBMET02824 | DBMET02816 | |
| 0.042 | 0.161 | 0.077 | Histone deacetylase SIRT3 inhibitor | 0.077 0.02 DBMET02816 | DBMET02816 | |
| 0.005 | 0.125 | 0.025 | Alpha 2c adrenoreceptor agonist | 0.025 0.007 DBMET02816 | DBMET02816 | |
| 0.015 | 0.135 | 0.036 | Calcium release-activated channel blocker | 0.036 0.019 DBMET02816 | DBMET02816 | |
| 0.012 | 0.132 | 0.026 | Vanilloid 2 agonist | 0.026 0.015 DBMET02816 | DBMET02816 | |
| 0.005 | 0.126 | 0.026 | Complement factor D inhibitor | 0.026 0.005 DBMET02816 | DBMET02816 | |
| 0.032 | 0.153 | 0.064 | Alpha 1b adrenoreceptor agonist | 0.055 0.025 DBMET02815 0.064 0.016 DBMET02816 | DBMET02816 | |
| 0.04 | 0.161 | 0.083 | Ornithine decarboxylase inhibitor | 0.083 0.064 DBMET02816 | DBMET02816 | |
| 0.024 | 0.146 | 0.051 | Kainate receptor agonist | 0.051 0.013 DBMET02816 | DBMET02816 | |
| 0.083 | 0.205 | 0.204 | Hexokinase inhibitor | 0.176 0.052 DBMET02815 0.204 0.033 DBMET02816 0.149 0.08 DBMET02821 0.167 0.061 DBMET02822 0.17 0.058 DBMET02823 0.164 0.064 DBMET02824 | DBMET02816 | |
| 0.012 | 0.135 | 0.035 | MAP3K8 inhibitor | 0.035 0.01 DBMET02816 | DBMET02816 | |
| 0.036 | 0.159 | 0.101 | Phosphodiesterase 1A inhibitor | 0.06 0.042 DBMET02814 0.061 0.039 DBMET02815 0.091 0.012 DBMET02816 0.101 0.01 DBMET02821 0.069 0.026 DBMET02822 0.059 0.043 DBMET02823 0.072 0.023 DBMET02824 | DBMET02821 | |
| 0.045 | 0.168 | 0.137 | CDK2/cyclin A inhibitor | 0.137 0.032 DBMET02815 0.107 0.052 DBMET02816 0.092 0.065 DBMET02821 | DBMET02815 | |
| 0.039 | 0.163 | 0.056 | Leukotriene C antagonist | 0.056 0.041 DBMET02816 | DBMET02816 | |
| 0.027 | 0.152 | 0.081 | Carbonic anhydrase stimulant | 0.058 0.043 DBMET02815 0.081 0.025 DBMET02816 | DBMET02816 | |
| 0.021 | 0.147 | 0.066 | Lysophosphatidic acid 3 receptor antagonist | 0.066 0.017 DBMET02816 | DBMET02816 | |
| 0.01 | 0.137 | 0.071 | Urate transporter 1 inhibitor | 0.071 0.01 DBMET02816 | DBMET02816 | |
| 0.017 | 0.145 | 0.04 | Melatonin receptor 1A agonist | 0.04 0.013 DBMET02816 | DBMET02816 | |
| 0.007 | 0.137 | 0.023 | Imidazoline I1 receptor antagonist | 0.023 0.012 DBMET02816 | DBMET02816 | |
| 0.066 | 0.195 | 0.145 | Photosensitizer | 0.145 0.034 DBMET02816 | DBMET02816 | |
| 0.085 | 0.217 | 0.124 | Neuropeptide Y1 antagonist | 0.124 0.113 DBMET02816 | DBMET02816 | |
| 0.079 | 0.211 | 0.199 | Arachidonic acid antagonist | 0.142 0.098 DBMET02815 0.199 0.033 DBMET02816 0.153 0.085 DBMET02822 | DBMET02816 | |
| 0.062 | 0.194 | 0.481 | Tyrosine kinase inhibitor | 0.146 0.091 DBMET02815 0.247 0.055 DBMET02816 0.379 0.031 DBMET02821 0.2 0.069 DBMET02822 0.481 0.019 DBMET02823 0.329 0.038 DBMET02824 | DBMET02823 | |
| 0.03 | 0.162 | 0.088 | Na+ K+ transporting ATPase inhibitor | 0.088 0.043 DBMET02816 | DBMET02816 | |
| 0.01 | 0.143 | 0.06 | Nicotinic acid receptor agonist | 0.041 0.02 DBMET02815 0.06 0.011 DBMET02816 | DBMET02816 | |
| 0.01 | 0.144 | 0.022 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.022 0.011 DBMET02816 | DBMET02816 | |
| 0.021 | 0.156 | 0.049 | Potassium channel Kv1.1 blocker | 0.035 0.034 DBMET02815 0.049 0.014 DBMET02816 | DBMET02816 | |
| 0.087 | 0.223 | 0.302 | MAP kinase kinase 2 inhibitor | 0.302 0.034 DBMET02815 0.25 0.054 DBMET02816 0.175 0.099 DBMET02824 | DBMET02815 | |
| 0.032 | 0.169 | 0.163 | Phosphodiesterase IV inhibitor | 0.163 0.019 DBMET02814 0.106 0.041 DBMET02815 0.107 0.04 DBMET02816 0.108 0.039 DBMET02821 0.111 0.037 DBMET02822 0.072 0.07 DBMET02823 0.078 0.063 DBMET02824 | DBMET02814 | |
| 0.028 | 0.166 | 0.081 | MAO B inhibitor | 0.081 0.075 DBMET02815 | DBMET02815 | |
| 0.016 | 0.154 | 0.047 | Thymidylate synthase inhibitor | 0.047 0.032 DBMET02816 | DBMET02816 | |
| 0.05 | 0.188 | 0.185 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.097 0.057 DBMET02815 0.185 0.018 DBMET02816 0.086 0.07 DBMET02823 | DBMET02816 | |
| 0.149 | 0.287 | 0.421 | Histamine release inhibitor | 0.396 0.078 DBMET02815 0.421 0.065 DBMET02816 0.208 0.192 DBMET02817 0.206 0.195 DBMET02818 0.218 0.183 DBMET02819 0.211 0.19 DBMET02821 0.301 0.123 DBMET02822 | DBMET02816 | |
| 0.016 | 0.154 | 0.028 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.028 0.014 DBMET02816 | DBMET02816 | |
| 0.024 | 0.162 | 0.066 | Purinergic P2X4 antagonist | 0.055 0.018 DBMET02815 0.066 0.011 DBMET02816 | DBMET02816 | |
| 0.009 | 0.148 | 0.034 | Methionyl aminopeptidase 1 inhibitor | 0.034 0.018 DBMET02816 | DBMET02816 | |
| 0.155 | 0.294 | 0.386 | Calcium channel activator | 0.225 0.179 DBMET02814 0.344 0.054 DBMET02815 0.386 0.03 DBMET02816 0.214 0.193 DBMET02821 | DBMET02816 | |
| 0.043 | 0.182 | 0.362 | Pim-1 kinase inhibitor | 0.152 0.027 DBMET02814 0.153 0.027 DBMET02815 0.115 0.045 DBMET02816 0.18 0.019 DBMET02821 0.131 0.035 DBMET02822 0.121 0.041 DBMET02823 0.362 0.005 DBMET02824 | DBMET02824 | |
| 0.025 | 0.165 | 0.059 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.059 0.04 DBMET02816 | DBMET02816 | |
| 0.055 | 0.195 | 0.116 | Beta glucuronidase inhibitor | 0.09 0.089 DBMET02815 0.116 0.05 DBMET02816 | DBMET02816 | |
| 0.036 | 0.175 | 0.18 | Fibroblast growth factor 1 antagonist | 0.18 0.022 DBMET02815 0.161 0.028 DBMET02816 | DBMET02815 | |
| 0.029 | 0.169 | 0.076 | Fibroblast growth factor 2 antagonist | 0.074 0.038 DBMET02815 0.076 0.037 DBMET02816 | DBMET02816 | |
| 0.024 | 0.165 | 0.076 | Glutamate (mGluR4) antagonist | 0.043 0.031 DBMET02815 0.076 0.009 DBMET02816 0.045 0.028 DBMET02824 | DBMET02816 | |
| 0.181 | 0.323 | 0.48 | MAP kinase 1 inhibitor | 0.3 0.18 DBMET00863 0.269 0.213 DBMET02814 0.48 0.061 DBMET02815 0.388 0.113 DBMET02816 0.409 0.101 DBMET02821 0.364 0.127 DBMET02822 0.422 0.093 DBMET02824 | DBMET02815 | |
| 0.037 | 0.18 | 0.424 | Phosphodiesterase 3A inhibitor | 0.135 0.018 DBMET02814 0.424 0.004 DBMET02815 0.163 0.013 DBMET02816 0.156 0.015 DBMET02818 0.128 0.02 DBMET02819 0.192 0.009 DBMET02821 0.166 0.013 DBMET02822 0.147 0.016 DBMET02823 0.118 0.023 DBMET02824 | DBMET02815 | |
| 0.027 | 0.17 | 0.771 | Check point kinase 1 inhibitor | 0.771 0.003 DBMET02815 0.117 0.021 DBMET02816 0.296 0.005 DBMET02818 0.186 0.01 DBMET02819 | DBMET02815 | |
| 0.015 | 0.158 | 0.049 | Stearoyl-CoA desaturase inhibitor | 0.049 0.024 DBMET02816 | DBMET02816 | |
| 0.024 | 0.167 | 0.08 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.08 0.016 DBMET02816 0.054 0.037 DBMET02822 | DBMET02816 | |
| 0.02 | 0.163 | 0.096 | Nicotinic neuronal receptor agonist | 0.057 0.038 DBMET02815 0.096 0.014 DBMET02816 | DBMET02816 | |
| 0.009 | 0.153 | 0.039 | 5 Hydroxytryptamine 3B antagonist | 0.039 0.022 DBMET02816 | DBMET02816 | |
| 0.087 | 0.231 | 0.394 | Anticonvulsant | 0.218 0.071 DBMET02814 0.168 0.109 DBMET02815 0.291 0.043 DBMET02816 0.148 0.132 DBMET02820 0.337 0.031 DBMET02821 0.175 0.103 DBMET02822 0.206 0.078 DBMET02823 0.394 0.022 DBMET02824 | DBMET02824 | |
| 0.048 | 0.194 | 0.274 | Protein kinase (CK1) inhibitor | 0.232 0.031 DBMET02815 0.274 0.021 DBMET02816 0.154 0.065 DBMET02821 0.136 0.078 DBMET02824 | DBMET02816 | |
| 0.036 | 0.182 | 0.107 | Stem cell growth factor agonist | 0.107 0.039 DBMET02824 | DBMET02824 | |
| 0.064 | 0.21 | 0.235 | NADPH oxidase inhibitor | 0.131 0.07 DBMET02814 0.224 0.027 DBMET02815 0.235 0.024 DBMET02816 0.137 0.064 DBMET02822 | DBMET02816 | |
| 0.035 | 0.181 | 0.117 | MAP kinase kinase 10 inhibitor | 0.081 0.028 DBMET02815 0.117 0.015 DBMET02816 0.066 0.046 DBMET02821 0.069 0.042 DBMET02824 | DBMET02816 | |
| 0.039 | 0.187 | 0.145 | Aminopeptidase B inhibitor | 0.145 0.04 DBMET02816 | DBMET02816 | |
| 0.016 | 0.164 | 0.071 | Glutamate (mGluR1) antagonist | 0.05 0.049 DBMET02815 0.071 0.029 DBMET02816 0.069 0.031 DBMET02824 | DBMET02816 | |
| 0.107 | 0.256 | 0.195 | Neurotensin receptor agonist | 0.145 0.116 DBMET00864 0.156 0.088 DBMET02815 0.195 0.038 DBMET02816 0.139 0.133 DBMET02821 0.164 0.071 DBMET02822 0.139 0.131 DBMET02824 | DBMET02816 | |
| 0.016 | 0.165 | 0.072 | Glutamate (mGluR5) agonist | 0.072 0.013 DBMET02816 | DBMET02816 | |
| 0.004 | 0.153 | 0.014 | NMDA receptor phencyclidine site antagonist | 0.014 0.012 DBMET02816 | DBMET02816 | |
| 0.01 | 0.161 | 0.02 | Toll-Like receptor 8 agonist | 0.02 0.013 DBMET02816 | DBMET02816 | |
| 0.059 | 0.21 | 0.468 | CDC-like kinase 2 inhibitor | 0.468 0.008 DBMET02815 0.322 0.026 DBMET02816 0.153 0.091 DBMET02818 0.224 0.055 DBMET02821 0.137 0.103 DBMET02822 0.138 0.102 DBMET02823 0.248 0.046 DBMET02824 | DBMET02815 | |
| 0.018 | 0.17 | 0.067 | Phosphatidylinositol 3-kinase beta inhibitor | 0.067 0.021 DBMET02816 | DBMET02816 | |
| 0.011 | 0.163 | 0.081 | AMPA receptor antagonist | 0.081 0.017 DBMET02815 0.079 0.017 DBMET02816 0.05 0.031 DBMET02821 0.044 0.038 DBMET02823 | DBMET02815 | |
| 0.053 | 0.205 | 0.266 | Nav1.6 sodium channel blocker | 0.121 0.094 DBMET02814 0.128 0.084 DBMET02815 0.266 0.008 DBMET02816 0.264 0.008 DBMET02821 0.205 0.018 DBMET02822 0.198 0.02 DBMET02823 0.164 0.04 DBMET02824 | DBMET02816 | |
| 0.042 | 0.194 | 0.093 | Orexin receptor 1 antagonist | 0.068 0.063 DBMET02814 0.093 0.018 DBMET02816 | DBMET02816 | |
| 0.028 | 0.181 | 0.09 | Carbonic anhydrase XIII inhibitor | 0.09 0.043 DBMET02816 | DBMET02816 | |
| 0.034 | 0.188 | 0.152 | Acetylcholine nicotinic agonist | 0.088 0.047 DBMET02815 0.152 0.016 DBMET02816 | DBMET02816 | |
| 0.051 | 0.204 | 0.211 | Bromodomain-containing protein 2 inhibitor | 0.122 0.022 DBMET02814 0.131 0.016 DBMET02815 0.147 0.01 DBMET02816 0.211 0.004 DBMET02821 0.176 0.005 DBMET02822 0.12 0.023 DBMET02823 0.085 0.065 DBMET02824 | DBMET02821 | |
| 0.004 | 0.158 | 0.036 | 5 Hydroxytryptamine 1D agonist | 0.036 0.016 DBMET02816 | DBMET02816 | |
| 0.013 | 0.167 | 0.133 | Phosphatidylinositol 3-kinase alpha inhibitor | 0.059 0.03 DBMET02815 0.133 0.012 DBMET02816 0.053 0.034 DBMET02824 | DBMET02816 | |
| 0.013 | 0.167 | 0.044 | Oxytocin agonist | 0.044 0.029 DBMET02816 | DBMET02816 | |
| 0.018 | 0.173 | 0.092 | Toll-Like receptor 8 antagonist | 0.054 0.037 DBMET02814 0.092 0.012 DBMET02816 0.071 0.023 DBMET02821 0.086 0.014 DBMET02823 0.084 0.015 DBMET02824 | DBMET02816 | |
| 0.062 | 0.216 | 0.475 | Protein kinase C nu inhibitor | 0.113 0.101 DBMET02814 0.475 0.005 DBMET02815 0.276 0.029 DBMET02816 0.14 0.075 DBMET02818 0.335 0.018 DBMET02821 0.24 0.036 DBMET02822 0.254 0.034 DBMET02823 0.175 0.057 DBMET02824 | DBMET02815 | |
| 0.032 | 0.187 | 0.078 | Pregnane X receptor antagonist | 0.078 0.008 DBMET02816 | DBMET02816 | |
| 0.02 | 0.176 | 0.082 | Adenylate cyclase 1 inhibitor | 0.082 0.007 DBMET02816 | DBMET02816 | |
| 0.023 | 0.18 | 0.208 | NMDA 2B receptor antagonist | 0.055 0.036 DBMET02815 0.208 0.005 DBMET02816 | DBMET02816 | |
| 0.023 | 0.181 | 0.059 | Cytokine production stimulant | 0.059 0.013 DBMET02816 | DBMET02816 | |
| 0.037 | 0.195 | 0.065 | Immunoglobulin Fc receptor antagonist | 0.065 0.015 DBMET02816 | DBMET02816 | |
| 0.016 | 0.175 | 0.031 | Glutamate (mGluR3) agonist | 0.031 0.026 DBMET02816 | DBMET02816 | |
| 0.008 | 0.167 | 0.023 | Lysophosphatidic acid 1 receptor antagonist | 0.023 0.012 DBMET02816 | DBMET02816 | |
| 0.014 | 0.173 | 0.053 | Glutamate (mGluR3) antagonist | 0.053 0.011 DBMET02816 | DBMET02816 | |
| 0.032 | 0.191 | 0.128 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.128 0.036 DBMET02815 0.1 0.053 DBMET02816 | DBMET02815 | |
| 0.007 | 0.167 | 0.027 | Sodium/glucose cotransporter 2 inhibitor | 0.027 0.017 DBMET02816 | DBMET02816 | |
| 0.021 | 0.182 | 0.061 | CC chemokine 4 receptor antagonist | 0.061 0.015 DBMET02816 | DBMET02816 | |
| 0.009 | 0.171 | 0.06 | Acetylcholine M1 receptor agonist | 0.06 0.022 DBMET02816 | DBMET02816 | |
| 0.008 | 0.17 | 0.021 | Glutaminyl-peptide cyclotransferase inhibitor | 0.021 0.016 DBMET02816 | DBMET02816 | |
| 0.024 | 0.186 | 0.075 | Glutamate (mGluR group III) antagonist | 0.043 0.031 DBMET02815 0.075 0.008 DBMET02816 0.045 0.027 DBMET02824 | DBMET02816 | |
| 0.039 | 0.202 | 0.266 | Polo-like kinase-4 inhibitor | 0.105 0.071 DBMET02814 0.266 0.006 DBMET02815 0.261 0.007 DBMET02816 | DBMET02815 | |
| 0.032 | 0.195 | 0.076 | Corticotropin releasing factor 2 receptor antagonist | 0.076 0.021 DBMET02816 | DBMET02816 | |
| 0.048 | 0.213 | 0.163 | TRKA antagonist | 0.163 0.043 DBMET02815 0.133 0.058 DBMET02816 0.127 0.062 DBMET02824 | DBMET02815 | |
| 0.01 | 0.176 | 0.031 | Acid ceramidase inhibitor | 0.031 0.009 DBMET02816 | DBMET02816 | |
| 0.035 | 0.202 | 0.133 | Histamine N-methyltransferase inhibitor | 0.133 0.022 DBMET02816 | DBMET02816 | |
| 0.022 | 0.19 | 0.071 | Potassium channel small-conductance Ca-activated blocker | 0.071 0.013 DBMET02816 0.041 0.038 DBMET02824 | DBMET02816 | |
| 0.03 | 0.199 | 0.13 | Polo-like kinase-2 inhibitor | 0.103 0.023 DBMET02814 0.083 0.041 DBMET02815 0.13 0.006 DBMET02816 0.088 0.036 DBMET02824 | DBMET02816 | |
| 0.05 | 0.222 | 0.14 | Electrolyte absorption antagonist | 0.11 0.045 DBMET02815 0.14 0.024 DBMET02816 | DBMET02816 | |
| 0.049 | 0.221 | 0.142 | Lanosterol 14 alpha demethylase inhibitor | 0.096 0.061 DBMET02815 0.142 0.015 DBMET02816 0.085 0.082 DBMET02824 | DBMET02816 | |
| 0.054 | 0.227 | 0.197 | Sodium channel blocker | 0.112 0.095 DBMET02815 0.197 0.033 DBMET02816 | DBMET02816 | |
| 0.014 | 0.188 | 0.078 | Phosphatidylinositol 3-kinase delta inhibitor | 0.073 0.028 DBMET02816 0.078 0.026 DBMET02824 | DBMET02824 | |
| 0.043 | 0.217 | 0.132 | Uric acid excretion stimulant | 0.091 0.063 DBMET00864 0.132 0.031 DBMET02815 0.116 0.04 DBMET02816 0.087 0.07 DBMET02817 0.088 0.069 DBMET02824 | DBMET02815 | |
| 0.041 | 0.216 | 0.148 | HIV-1 integrase (Overall Integration) inhibitor | 0.148 0.026 DBMET02816 | DBMET02816 | |
| 0.008 | 0.183 | 0.033 | Phosphoglycerate kinase inhibitor | 0.033 0.027 DBMET02816 | DBMET02816 | |
| 0.026 | 0.202 | 0.106 | CDK1/cyclin B1 inhibitor | 0.065 0.053 DBMET02815 0.071 0.047 DBMET02816 0.106 0.026 DBMET02821 0.074 0.043 DBMET02822 0.105 0.027 DBMET02823 | DBMET02821 | |
| 0.008 | 0.184 | 0.02 | Retinoid X beta receptor antagonist | 0.02 0.017 DBMET02816 | DBMET02816 | |
| 0.026 | 0.202 | 0.068 | 5 Hydroxytryptamine 7 agonist | 0.068 0.021 DBMET02816 | DBMET02816 | |
| 0.02 | 0.196 | 0.08 | Alpha 2 adrenoreceptor agonist | 0.08 0.024 DBMET02816 | DBMET02816 | |
| 0.058 | 0.234 | 0.126 | Glutamate release inhibitor | 0.126 0.018 DBMET02816 | DBMET02816 | |
| 0.014 | 0.191 | 0.049 | Adenosine deaminase inhibitor | 0.049 0.031 DBMET02816 | DBMET02816 | |
| 0.012 | 0.19 | 0.039 | Histone deacetylase 7 inhibitor | 0.039 0.024 DBMET02816 | DBMET02816 | |
| 0.01 | 0.189 | 0.058 | Guanylate cyclase inhibitor | 0.058 0.013 DBMET02816 | DBMET02816 | |
| 0.03 | 0.209 | 0.122 | Protein kinase B alpha inhibitor | 0.085 0.038 DBMET02815 0.122 0.017 DBMET02816 0.062 0.058 DBMET02821 0.119 0.019 DBMET02824 | DBMET02816 | |
| 0.011 | 0.191 | 0.03 | Glutamate (mGluR1) agonist | 0.03 0.01 DBMET02816 | DBMET02816 | |
| 0.032 | 0.213 | 0.217 | MAP kinase kinase kinase inhibitor | 0.121 0.05 DBMET02814 0.176 0.025 DBMET02815 0.146 0.037 DBMET02816 0.109 0.059 DBMET02821 0.217 0.015 DBMET02824 | DBMET02824 | |
| 0.033 | 0.214 | 0.141 | Acetylcholine agonist | 0.141 0.029 DBMET02816 | DBMET02816 | |
| 0.085 | 0.266 | 0.192 | CF transmembrane conductance regulator agonist | 0.171 0.045 DBMET02815 0.192 0.027 DBMET02816 | DBMET02816 | |
| 0.029 | 0.211 | 0.094 | Bcr-Abl kinase inhibitor | 0.093 0.049 DBMET02816 0.094 0.047 DBMET02821 0.089 0.053 DBMET02822 0.092 0.05 DBMET02824 | DBMET02821 | |
| 0.067 | 0.25 | 0.482 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.482 0.007 DBMET02815 0.288 0.035 DBMET02816 0.157 0.089 DBMET02818 0.204 0.064 DBMET02824 | DBMET02815 | |
| 0.01 | 0.193 | 0.083 | Oleamide hydrolase inhibitor | 0.083 0.012 DBMET02816 | DBMET02816 | |
| 0.021 | 0.205 | 0.108 | Amidase inhibitor | 0.108 0.02 DBMET02816 0.076 0.041 DBMET02820 | DBMET02816 | |
| 0.016 | 0.199 | 0.081 | Fibroblast growth factor 4 antagonist | 0.065 0.032 DBMET02815 0.081 0.017 DBMET02816 0.056 0.043 DBMET02824 | DBMET02816 | |
| 0.059 | 0.243 | 0.129 | CDC-like kinase 3 inhibitor | 0.115 0.051 DBMET02815 0.129 0.033 DBMET02816 0.103 0.073 DBMET02824 | DBMET02816 | |
| 0.005 | 0.189 | 0.049 | Orexin receptor 2 antagonist | 0.049 0.014 DBMET02816 | DBMET02816 | |
| 0.004 | 0.189 | 0.014 | 5 Lipoxygenase activating protein inhibitor | 0.014 0.01 DBMET02816 | DBMET02816 | |
| 0.012 | 0.197 | 0.079 | 5 Hydroxytryptamine 2 agonist | 0.079 0.016 DBMET02816 | DBMET02816 | |
| 0.007 | 0.193 | 0.036 | Free fatty acid receptor 1 antagonist | 0.036 0.021 DBMET02816 | DBMET02816 | |
| 0.028 | 0.214 | 0.114 | Phosphodiesterase 1B inhibitor | 0.089 0.018 DBMET02814 0.098 0.015 DBMET02816 0.108 0.012 DBMET02821 0.091 0.017 DBMET02822 0.072 0.029 DBMET02823 0.114 0.011 DBMET02824 | DBMET02824 | |
| 0.025 | 0.211 | 0.065 | MAP kinase kinase 9 inhibitor | 0.063 0.027 DBMET02816 0.051 0.048 DBMET02821 0.065 0.025 DBMET02824 | DBMET02824 | |
| 0.014 | 0.202 | 0.079 | Dihydroorotate dehydrogenase inhibitor | 0.058 0.029 DBMET02816 0.07 0.022 DBMET02821 0.079 0.018 DBMET02822 0.058 0.03 DBMET02823 | DBMET02822 | |
| 0.036 | 0.225 | 0.098 | Transforming growth factor antagonist | 0.075 0.041 DBMET02815 0.098 0.022 DBMET02816 0.063 0.059 DBMET02824 | DBMET02816 | |
| 0.007 | 0.197 | 0.066 | TRPM8 blocker | 0.066 0.01 DBMET02816 | DBMET02816 | |
| 0.005 | 0.196 | 0.045 | Glutamate (mGluR2) antagonist | 0.045 0.01 DBMET02816 0.032 0.017 DBMET02821 0.028 0.024 DBMET02823 | DBMET02816 | |
| 0.022 | 0.212 | 0.077 | Aldosterone antagonist | 0.077 0.012 DBMET02816 | DBMET02816 | |
| 0.009 | 0.2 | 0.024 | Thyroid hormone agonist | 0.024 0.023 DBMET02815 | DBMET02815 | |
| 0.056 | 0.249 | 0.102 | CC chemokine 5 receptor agonist | 0.102 0.019 DBMET02816 0.088 0.042 DBMET02821 0.099 0.023 DBMET02822 | DBMET02816 | |
| 0.042 | 0.235 | 0.189 | Phosphodiesterase I inhibitor | 0.14 0.019 DBMET02814 0.121 0.027 DBMET02816 0.189 0.012 DBMET02821 0.167 0.014 DBMET02822 0.125 0.025 DBMET02823 0.142 0.019 DBMET02824 | DBMET02821 | |
| 0.011 | 0.204 | 0.074 | Glutamate (mGluR group I) agonist | 0.074 0.014 DBMET02816 | DBMET02816 | |
| 0.037 | 0.231 | 0.102 | Keratolytic | 0.102 0.029 DBMET02816 | DBMET02816 | |
| 0.008 | 0.203 | 0.025 | Sodium/glucose cotransporter inhibitor | 0.025 0.02 DBMET02816 | DBMET02816 | |
| 0.019 | 0.214 | 0.069 | Nicotinic alpha7 receptor agonist | 0.061 0.03 DBMET02815 0.069 0.024 DBMET02816 | DBMET02816 | |
| 0.018 | 0.215 | 0.043 | Thymidine kinase inhibitor | 0.043 0.025 DBMET02816 | DBMET02816 | |
| 0.036 | 0.234 | 0.093 | Glycine receptor agonist | 0.093 0.026 DBMET02816 | DBMET02816 | |
| 0.013 | 0.211 | 0.049 | Delayed rectifier potassium channel blocker | 0.049 0.012 DBMET02816 | DBMET02816 | |
| 0.019 | 0.217 | 0.285 | MAP kinase 14 inhibitor | 0.067 0.058 DBMET02815 0.285 0.006 DBMET02816 | DBMET02816 | |
| 0.046 | 0.244 | 0.16 | Carbonic anhydrase III inhibitor | 0.16 0.025 DBMET02816 0.108 0.054 DBMET02822 | DBMET02816 | |
| 0.005 | 0.203 | 0.035 | Acetylcholine M4 receptor agonist | 0.035 0.017 DBMET02816 | DBMET02816 | |
| 0.032 | 0.231 | 0.141 | Alcohol dehydrogenase inhibitor | 0.141 0.023 DBMET02815 0.126 0.031 DBMET02816 | DBMET02815 | |
| 0.01 | 0.209 | 0.028 | Integrin alpha2beta1 antagonist | 0.028 0.016 DBMET02816 | DBMET02816 | |
| 0.01 | 0.209 | 0.071 | Acetylcholine muscarinic agonist | 0.071 0.026 DBMET02816 | DBMET02816 | |
| 0.024 | 0.226 | 0.197 | Protein kinase C alpha inhibitor | 0.197 0.005 DBMET02815 0.102 0.022 DBMET02816 | DBMET02815 | |
| 0.076 | 0.278 | 0.164 | Adenylate cyclase stimulant | 0.164 0.042 DBMET02816 0.123 0.117 DBMET02822 | DBMET02816 | |
| 0.045 | 0.249 | 0.2 | Tyrosine-protein kinase receptor antagonist | 0.2 0.04 DBMET02815 0.131 0.077 DBMET02816 0.131 0.077 DBMET02824 | DBMET02815 | |
| 0.082 | 0.285 | 0.497 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.497 0.007 DBMET02815 0.306 0.035 DBMET02816 0.286 0.04 DBMET02818 0.169 0.105 DBMET02819 0.154 0.122 DBMET02824 | DBMET02815 | |
| 0.085 | 0.289 | 0.249 | Neurotrophic factor enhancer | 0.173 0.106 DBMET02815 0.249 0.039 DBMET02816 0.183 0.095 DBMET02822 | DBMET02816 | |
| 0.034 | 0.239 | 0.519 | Glycogen synthase kinase-3 inhibitor | 0.1 0.08 DBMET00863 0.519 0.005 DBMET02815 0.194 0.033 DBMET02816 0.284 0.017 DBMET02818 0.197 0.032 DBMET02819 0.233 0.024 DBMET02824 | DBMET02815 | |
| 0.008 | 0.214 | 0.059 | Glutamate (mGluR group II) antagonist | 0.059 0.011 DBMET02816 0.043 0.022 DBMET02821 0.034 0.032 DBMET02822 0.039 0.026 DBMET02823 0.037 0.029 DBMET02824 | DBMET02816 | |
| 0.004 | 0.21 | 0.019 | Inosine monophosphate dehydrogenase 2 inhibitor | 0.019 0.014 DBMET02816 | DBMET02816 | |
| 0.017 | 0.223 | 0.042 | AICAR transformylase inhibitor | 0.042 0.033 DBMET02816 | DBMET02816 | |
| 0.027 | 0.233 | 0.311 | Protein kinase A inhibitor | 0.311 0.005 DBMET02815 0.198 0.014 DBMET02816 0.092 0.051 DBMET02824 | DBMET02815 | |
| 0.014 | 0.221 | 0.059 | Glutamate (mGluR1a) antagonist | 0.059 0.015 DBMET02815 0.051 0.02 DBMET02816 | DBMET02815 | |
| 0.034 | 0.241 | 0.585 | Hepatocyte growth factor antagonist | 0.152 0.022 DBMET02814 0.136 0.027 DBMET02815 0.215 0.009 DBMET02816 0.386 0.004 DBMET02821 0.277 0.005 DBMET02822 0.585 0.003 DBMET02823 0.222 0.008 DBMET02824 | DBMET02823 | |
| 0.112 | 0.319 | 0.271 | RNA-directed DNA polymerase inhibitor | 0.192 0.111 DBMET02815 0.271 0.039 DBMET02816 0.18 0.133 DBMET02823 0.167 0.158 DBMET02824 | DBMET02816 | |
| 0.025 | 0.233 | 0.088 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.088 0.044 DBMET02816 | DBMET02816 | |
| 0.006 | 0.216 | 0.044 | Glucose-dependent insulinotropic receptor agonist | 0.041 0.016 DBMET02816 0.044 0.014 DBMET02824 | DBMET02824 | |
| 0.01 | 0.225 | 0.08 | Aromatase inhibitor | 0.08 0.028 DBMET02816 | DBMET02816 | |
| 0.008 | 0.224 | 0.032 | Retinoid X alpha receptor agonist | 0.032 0.028 DBMET02816 | DBMET02816 | |
| 0.011 | 0.227 | 0.066 | Raf kinase B inhibitor | 0.066 0.036 DBMET02815 | DBMET02815 | |
| 0.018 | 0.235 | 0.106 | Neuronal nicotinic receptor antagonist | 0.106 0.022 DBMET02816 | DBMET02816 | |
| 0.044 | 0.262 | 0.13 | Caspase 3 inhibitor | 0.099 0.093 DBMET02816 0.13 0.047 DBMET02817 | DBMET02817 | |
| 0.046 | 0.265 | 0.216 | Cytidine deaminase inhibitor | 0.121 0.099 DBMET02814 0.183 0.055 DBMET02816 0.216 0.04 DBMET02821 0.145 0.079 DBMET02822 0.18 0.057 DBMET02823 0.156 0.071 DBMET02824 | DBMET02821 | |
| 0.017 | 0.236 | 0.055 | Histamine agonist | 0.055 0.033 DBMET02816 | DBMET02816 | |
| 0.026 | 0.247 | 0.086 | Orexin receptor antagonist | 0.086 0.021 DBMET02816 | DBMET02816 | |
| 0.042 | 0.264 | 0.121 | MAP kinase kinase 1 inhibitor | 0.097 0.06 DBMET02815 0.121 0.034 DBMET02816 | DBMET02816 | |
| 0.014 | 0.237 | 0.048 | Dihydroorotase inhibitor | 0.048 0.026 DBMET02816 | DBMET02816 | |
| 0.014 | 0.237 | 0.111 | Acetylcholine M5 receptor agonist | 0.111 0.015 DBMET02816 | DBMET02816 | |
| 0.018 | 0.242 | 0.051 | Protein kinase C eta inhibitor | 0.051 0.042 DBMET02816 | DBMET02816 | |
| 0.039 | 0.263 | 0.443 | GABA receptor agonist | 0.119 0.058 DBMET00863 0.252 0.01 DBMET02814 0.098 0.079 DBMET02815 0.191 0.02 DBMET02816 0.419 0.004 DBMET02821 0.312 0.005 DBMET02822 0.305 0.006 DBMET02823 0.443 0.004 DBMET02824 | DBMET02824 | |
| 0.077 | 0.301 | 0.177 | Interferon gamma antagonist | 0.177 0.052 DBMET02816 0.139 0.094 DBMET02822 | DBMET02816 | |
| 0.019 | 0.244 | 0.086 | Acetylcholine M4 receptor antagonist | 0.086 0.04 DBMET02816 | DBMET02816 | |
| 0.01 | 0.235 | 0.043 | GABA uptake inhibitor | 0.043 0.022 DBMET02816 | DBMET02816 | |
| 0.061 | 0.287 | 0.137 | Aurora-C kinase inhibitor | 0.126 0.091 DBMET02816 0.137 0.069 DBMET02824 | DBMET02824 | |
| 0.005 | 0.232 | 0.019 | Calcitonin gene-related peptide 1 receptor antagonist | 0.019 0.009 DBMET02815 | DBMET02815 | |
| 0.032 | 0.26 | 0.069 | Ryanodine receptor antagonist | 0.069 0.019 DBMET02816 | DBMET02816 | |
| 0.041 | 0.269 | 0.153 | MAP kinase kinase inhibitor | 0.135 0.061 DBMET02815 0.153 0.05 DBMET02816 | DBMET02816 | |
| 0.115 | 0.344 | 0.286 | Insulysin inhibitor | 0.223 0.125 DBMET02815 0.286 0.068 DBMET02816 0.206 0.147 DBMET02817 | DBMET02816 | |
| 0.017 | 0.247 | 0.097 | Vanilloid antagonist | 0.097 0.037 DBMET02816 | DBMET02816 | |
| 0.016 | 0.247 | 0.04 | Transforming growth factor beta 2 antagonist | 0.032 0.025 DBMET02815 0.04 0.012 DBMET02816 0.031 0.029 DBMET02824 | DBMET02816 | |
| 0.038 | 0.268 | 0.102 | Polo-like kinase-1 inhibitor | 0.09 0.062 DBMET02815 0.102 0.043 DBMET02816 0.089 0.064 DBMET02824 | DBMET02816 | |
| 0.04 | 0.27 | 0.09 | Vanilloid 4 agonist | 0.09 0.026 DBMET02816 | DBMET02816 | |
| 0.029 | 0.261 | 0.195 | Protein-tyrosine kinase Lyn inhibitor | 0.135 0.074 DBMET02815 0.195 0.048 DBMET02816 0.109 0.094 DBMET02824 | DBMET02816 | |
| 0.071 | 0.304 | 0.157 | Melanin inhibitor | 0.157 0.073 DBMET02816 0.127 0.12 DBMET02822 | DBMET02816 | |
| 0.019 | 0.251 | 0.044 | Vanilloid 3 antagonist | 0.044 0.014 DBMET02816 | DBMET02816 | |
| 0.034 | 0.267 | 0.084 | Phosphodiesterase VI inhibitor | 0.084 0.035 DBMET02816 0.074 0.053 DBMET02821 0.073 0.056 DBMET02822 | DBMET02816 | |
| 0.009 | 0.243 | 0.119 | NMDA 2 receptor antagonist | 0.119 0.024 DBMET02816 | DBMET02816 | |
| 0.02 | 0.254 | 0.063 | Sphingosine kinase 2 inhibitor | 0.063 0.028 DBMET02816 | DBMET02816 | |
| 0.014 | 0.251 | 0.14 | TRPA1 antagonist | 0.117 0.014 DBMET02815 0.14 0.011 DBMET02816 | DBMET02816 | |
| 0.049 | 0.287 | 0.167 | Toll-Like receptor 2 antagonist | 0.167 0.042 DBMET02816 0.114 0.084 DBMET02822 | DBMET02816 | |
| 0.016 | 0.254 | 0.127 | Phosphatidylinositol kinase inhibitor | 0.057 0.044 DBMET02815 0.127 0.015 DBMET02816 0.089 0.024 DBMET02824 | DBMET02816 | |
| 0.029 | 0.267 | 0.477 | Glycogen synthase kinase-3 beta inhibitor | 0.093 0.088 DBMET00863 0.477 0.005 DBMET02815 0.156 0.04 DBMET02816 0.274 0.016 DBMET02818 0.188 0.032 DBMET02819 0.233 0.022 DBMET02824 | DBMET02815 | |
| 0.007 | 0.246 | 0.265 | Phosphodiesterase X inhibitor | 0.172 0.005 DBMET02816 0.265 0.004 DBMET02821 0.136 0.007 DBMET02822 0.111 0.009 DBMET02823 0.054 0.025 DBMET02824 | DBMET02821 | |
| 0.007 | 0.246 | 0.265 | Phosphodiesterase 10A inhibitor | 0.172 0.005 DBMET02816 0.265 0.004 DBMET02821 0.136 0.007 DBMET02822 0.111 0.009 DBMET02823 0.054 0.025 DBMET02824 | DBMET02821 | |
| 0.009 | 0.248 | 0.048 | Inosine monophosphate dehydrogenase inhibitor | 0.048 0.016 DBMET02816 | DBMET02816 | |
| 0.017 | 0.257 | 0.098 | Catalase inhibitor | 0.098 0.039 DBMET02816 | DBMET02816 | |
| 0.022 | 0.263 | 0.052 | Sphingosine 1-phosphate receptor 1 antagonist | 0.052 0.048 DBMET02816 | DBMET02816 | |
| 0.014 | 0.256 | 0.056 | Benzodiazepine antagonist | 0.056 0.017 DBMET02816 0.05 0.027 DBMET02821 | DBMET02816 | |
| 0.013 | 0.255 | 0.037 | Integrin alpha2 antagonist | 0.037 0.025 DBMET02816 | DBMET02816 | |
| 0.022 | 0.265 | 0.091 | Phospholipase D inhibitor | 0.091 0.021 DBMET02816 | DBMET02816 | |
| 0.04 | 0.283 | 0.334 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.334 0.012 DBMET02815 0.229 0.038 DBMET02816 0.103 0.1 DBMET02818 0.141 0.07 DBMET02824 | DBMET02815 | |
| 0.013 | 0.258 | 0.075 | Raf kinase inhibitor | 0.075 0.05 DBMET02815 0.07 0.055 DBMET02816 | DBMET02815 | |
| 0.014 | 0.26 | 0.096 | Nicotinic receptor alpha4 subunit antagonist | 0.096 0.009 DBMET02816 | DBMET02816 | |
| 0.032 | 0.278 | 0.378 | GABA A receptor agonist | 0.208 0.009 DBMET02814 0.081 0.062 DBMET02815 0.139 0.018 DBMET02816 0.297 0.005 DBMET02821 0.211 0.009 DBMET02822 0.227 0.007 DBMET02823 0.378 0.004 DBMET02824 | DBMET02824 | |
| 0.018 | 0.265 | 0.152 | Vanilloid 1 antagonist | 0.152 0.014 DBMET02816 | DBMET02816 | |
| 0.014 | 0.261 | 0.058 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.058 0.034 DBMET02816 | DBMET02816 | |
| 0.064 | 0.311 | 0.511 | Death-associated protein kinase 3 inhibitor | 0.17 0.096 DBMET02814 0.511 0.005 DBMET02815 0.336 0.029 DBMET02816 0.212 0.068 DBMET02818 0.229 0.06 DBMET02819 0.174 0.093 DBMET02821 0.153 0.117 DBMET02822 0.233 0.059 DBMET02824 | DBMET02815 | |
| 0.093 | 0.342 | 0.274 | DNA synthesis inhibitor | 0.238 0.075 DBMET02815 0.274 0.053 DBMET02816 0.231 0.081 DBMET02821 0.247 0.069 DBMET02822 0.233 0.08 DBMET02823 0.182 0.151 DBMET02824 | DBMET02816 | |
| 0.011 | 0.26 | 0.067 | Bruton tyrosine kinase inhibitor | 0.058 0.038 DBMET02815 0.067 0.028 DBMET02816 | DBMET02816 | |
| 0.04 | 0.288 | 0.076 | Calcium channel P-type blocker | 0.076 0.019 DBMET02816 | DBMET02816 | |
| 0.01 | 0.259 | 0.051 | Adenosine A2b receptor antagonist | 0.05 0.034 DBMET02816 0.051 0.032 DBMET02824 | DBMET02824 | |
| 0.065 | 0.315 | 0.14 | Sphingosine 1-phosphate receptor 2 antagonist | 0.14 0.055 DBMET02816 0.115 0.11 DBMET02824 | DBMET02816 | |
| 0.041 | 0.291 | 0.239 | Protein kinase (CK1) gamma 2 inhibitor | 0.239 0.023 DBMET02815 0.201 0.032 DBMET02816 0.122 0.063 DBMET02824 | DBMET02815 | |
| 0.039 | 0.29 | 0.441 | Protein kinase (CK1) gamma inhibitor | 0.441 0.005 DBMET02815 0.227 0.036 DBMET02816 0.15 0.067 DBMET02818 0.137 0.076 DBMET02819 0.133 0.078 DBMET02824 | DBMET02815 | |
| 0.026 | 0.28 | 0.088 | Macrophage migration inhibitory factor inhibitor | 0.088 0.043 DBMET02816 | DBMET02816 | |
| 0.076 | 0.332 | 0.229 | Focal adhesion kinase 2 inhibitor | 0.229 0.049 DBMET02815 0.213 0.06 DBMET02816 0.157 0.119 DBMET02821 | DBMET02815 | |
| 0.025 | 0.281 | 0.057 | Glucosylceramidase inhibitor | 0.057 0.035 DBMET02816 | DBMET02816 | |
| 0.071 | 0.327 | 0.192 | Calpain inhibitor | 0.192 0.121 DBMET02816 | DBMET02816 | |
| 0.02 | 0.276 | 0.134 | MAP3K7 inhibitor | 0.09 0.029 DBMET02814 0.071 0.052 DBMET02815 0.115 0.016 DBMET02816 0.076 0.045 DBMET02821 0.067 0.059 DBMET02822 0.134 0.011 DBMET02824 | DBMET02824 | |
| 0.039 | 0.296 | 0.456 | Clk dual-specificity kinase inhibitor | 0.207 0.075 DBMET02814 0.456 0.011 DBMET02815 0.341 0.03 DBMET02816 0.21 0.074 DBMET02821 0.155 0.109 DBMET02822 0.277 0.045 DBMET02824 | DBMET02815 | |
| 0.008 | 0.265 | 0.044 | Cyclin D3 inhibitor | 0.044 0.025 DBMET02816 | DBMET02816 | |
| 0.006 | 0.263 | 0.072 | CDK2/cyclin E inhibitor | 0.072 0.034 DBMET02815 0.052 0.051 DBMET02816 | DBMET02815 | |
| 0.006 | 0.264 | 0.027 | Myristoyl transferase inhibitor | 0.027 0.018 DBMET02816 | DBMET02816 | |
| 0.053 | 0.311 | 0.214 | Anesthetic general | 0.214 0.067 DBMET02816 | DBMET02816 | |
| 0.013 | 0.271 | 0.037 | AMPA 4 receptor antagonist | 0.037 0.034 DBMET02816 | DBMET02816 | |
| 0.005 | 0.264 | 0.035 | Farnesoid X receptor agonist | 0.035 0.03 DBMET02816 | DBMET02816 | |
| 0.016 | 0.276 | 0.117 | Nicotinic alpha4beta2 receptor antagonist | 0.117 0.019 DBMET02816 | DBMET02816 | |
| 0.031 | 0.292 | 0.119 | Sphingomyelinase inhibitor | 0.119 0.042 DBMET02816 | DBMET02816 | |
| 0.047 | 0.307 | 0.179 | Toll-Like receptor antagonist | 0.179 0.039 DBMET02816 0.12 0.085 DBMET02823 | DBMET02816 | |
| 0.019 | 0.281 | 0.052 | Squalene epoxidase inhibitor | 0.052 0.031 DBMET02816 | DBMET02816 | |
| 0.009 | 0.273 | 0.128 | Raf kinase C inhibitor | 0.128 0.018 DBMET02815 0.079 0.032 DBMET02816 | DBMET02815 | |
| 0.07 | 0.334 | 0.169 | Pregnane X receptor agonist | 0.125 0.115 DBMET02814 0.169 0.027 DBMET02816 0.135 0.087 DBMET02821 0.126 0.11 DBMET02822 0.133 0.09 DBMET02824 | DBMET02816 | |
| 0.016 | 0.281 | 0.066 | Alpha adrenoreceptor agonist | 0.066 0.049 DBMET02816 | DBMET02816 | |
| 0.026 | 0.292 | 0.342 | RET inhibitor | 0.125 0.075 DBMET02814 0.278 0.027 DBMET02815 0.244 0.032 DBMET02816 0.134 0.07 DBMET02821 0.111 0.086 DBMET02822 0.342 0.016 DBMET02824 | DBMET02824 | |
| 0.022 | 0.291 | 0.082 | Potassium channel intermediate-conductance Ca-activated blocker | 0.082 0.016 DBMET02816 0.063 0.037 DBMET02821 0.056 0.051 DBMET02824 | DBMET02816 | |
| 0.012 | 0.281 | 0.051 | 5 Hydroxytryptamine 6 antagonist | 0.051 0.047 DBMET02816 | DBMET02816 | |
| 0.029 | 0.298 | 0.312 | MAP kinase 9 inhibitor | 0.155 0.036 DBMET02815 0.312 0.011 DBMET02816 0.116 0.052 DBMET02821 | DBMET02816 | |
| 0.049 | 0.32 | 0.161 | TRPA1 agonist | 0.161 0.024 DBMET02816 | DBMET02816 | |
| 0.023 | 0.296 | 0.124 | Protein kinase B beta inhibitor | 0.124 0.014 DBMET02815 0.093 0.03 DBMET02816 0.085 0.037 DBMET02821 0.097 0.027 DBMET02824 | DBMET02815 | |
| 0.024 | 0.297 | 0.1 | Glycine receptor antagonist | 0.1 0.032 DBMET02816 | DBMET02816 | |
| 0.012 | 0.285 | 0.036 | Ceramide glucosyltransferase inhibitor | 0.036 0.024 DBMET02816 | DBMET02816 | |
| 0.057 | 0.33 | 0.144 | Transcription factor STAT6 inhibitor | 0.144 0.028 DBMET02816 0.102 0.101 DBMET02822 0.114 0.071 DBMET02823 | DBMET02816 | |
| 0.021 | 0.295 | 0.23 | Benzodiazepine inverse agonist | 0.135 0.004 DBMET02814 0.054 0.02 DBMET02816 0.193 0.003 DBMET02821 0.094 0.005 DBMET02822 0.123 0.004 DBMET02823 0.23 0.003 DBMET02824 | DBMET02824 | |
| 0.012 | 0.286 | 0.042 | Nicotinic receptor alpha3 subunit antagonist | 0.042 0.032 DBMET02816 | DBMET02816 | |
| 0.044 | 0.318 | 0.157 | Nav1.5 sodium channel blocker | 0.157 0.023 DBMET02816 0.134 0.039 DBMET02821 0.098 0.09 DBMET02822 0.104 0.078 DBMET02823 0.1 0.084 DBMET02824 | DBMET02816 | |
| 0.047 | 0.321 | 0.149 | Acetylcholine release stimulant | 0.149 0.017 DBMET02816 | DBMET02816 | |
| 0.022 | 0.296 | 0.062 | Nicotinic alpha3beta2 receptor antagonist | 0.062 0.024 DBMET02816 | DBMET02816 | |
| 0.017 | 0.291 | 0.119 | Acetylcholine nicotinic antagonist | 0.119 0.03 DBMET02816 | DBMET02816 | |
| 0.03 | 0.305 | 0.095 | Potassium channel (Voltage-sensitive) activator | 0.095 0.06 DBMET02816 | DBMET02816 | |
| 0.039 | 0.315 | 0.069 | MDM2 inhibitor | 0.069 0.04 DBMET02816 | DBMET02816 | |
| 0.017 | 0.295 | 0.084 | NMDA receptor antagonist | 0.084 0.061 DBMET02815 0.08 0.066 DBMET02816 | DBMET02815 | |
| 0.046 | 0.324 | 0.121 | Glutamate (mGluR7) agonist | 0.121 0.029 DBMET02816 | DBMET02816 | |
| 0.004 | 0.283 | 0.045 | G protein-coupled receptor agonist | 0.045 0.021 DBMET02816 0.044 0.021 DBMET02824 | DBMET02816 | |
| 0.024 | 0.303 | 0.047 | CD45 antagonist | 0.047 0.043 DBMET02816 | DBMET02816 | |
| 0.011 | 0.294 | 0.065 | NMDA receptor glycine site agonist | 0.065 0.04 DBMET02816 | DBMET02816 | |
| 0.023 | 0.306 | 0.062 | Protease 3C (Human rhinovirus) inhibitor | 0.062 0.048 DBMET02816 | DBMET02816 | |
| 0.042 | 0.325 | 0.371 | Protein kinase (CK1) gamma 1 inhibitor | 0.371 0.011 DBMET02815 0.206 0.04 DBMET02816 0.114 0.105 DBMET02818 0.178 0.051 DBMET02824 | DBMET02815 | |
| 0.092 | 0.376 | 0.131 | CC chemokine 6 receptor antagonist | 0.131 0.069 DBMET00863 0.126 0.087 DBMET00864 | DBMET00863 | |
| 0.063 | 0.348 | 0.149 | Non-steroidal antiinflammatory agent | 0.149 0.116 DBMET02816 | DBMET02816 | |
| 0.012 | 0.297 | 0.757 | Poly(ADP-ribose) polymerase inhibitor | 0.757 0.002 DBMET02815 0.671 0.002 DBMET02818 0.629 0.003 DBMET02819 | DBMET02815 | |
| 0.007 | 0.293 | 0.233 | Phosphodiesterase II inhibitor | 0.131 0.006 DBMET02814 0.052 0.044 DBMET02816 0.233 0.004 DBMET02821 0.168 0.005 DBMET02822 0.149 0.005 DBMET02823 0.197 0.004 DBMET02824 | DBMET02821 | |
| 0.035 | 0.322 | 0.457 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.457 0.009 DBMET02815 0.255 0.044 DBMET02816 0.221 0.055 DBMET02818 0.124 0.112 DBMET02824 | DBMET02815 | |
| 0.014 | 0.301 | 0.049 | Diacylglycerol O-acyltransferase inhibitor | 0.049 0.037 DBMET02816 | DBMET02816 | |
| 0.023 | 0.311 | 0.09 | Secretase beta inhibitor | 0.09 0.025 DBMET02816 | DBMET02816 | |
| 0.028 | 0.317 | 0.111 | Gastric antisecretory | 0.111 0.052 DBMET02816 | DBMET02816 | |
| 0.027 | 0.317 | 0.129 | DNA intercalator | 0.129 0.053 DBMET02816 | DBMET02816 | |
| 0.017 | 0.307 | 0.048 | Potassium channel (ATP-sensitive) activator | 0.045 0.04 DBMET02815 0.048 0.033 DBMET02816 | DBMET02816 | |
| 0.036 | 0.327 | 0.134 | MAP kinase 13 inhibitor | 0.131 0.047 DBMET02815 0.114 0.062 DBMET02816 0.134 0.045 DBMET02821 0.113 0.063 DBMET02824 | DBMET02821 | |
| 0.01 | 0.303 | 0.247 | Smo receptor antagonist | 0.247 0.005 DBMET02814 0.145 0.005 DBMET02821 0.042 0.028 DBMET02823 0.106 0.007 DBMET02824 | DBMET02814 | |
| 0.018 | 0.311 | 0.051 | Potassium channel (Inward rectifier) activator | 0.047 0.041 DBMET02815 0.051 0.034 DBMET02816 | DBMET02816 | |
| 0.026 | 0.32 | 0.139 | Cholesterol synthesis inhibitor | 0.125 0.061 DBMET02816 0.108 0.077 DBMET02821 0.139 0.051 DBMET02822 0.097 0.091 DBMET02823 | DBMET02822 | |
| 0.035 | 0.33 | 0.137 | Nav1.3 sodium channel blocker | 0.137 0.058 DBMET02816 | DBMET02816 | |
| 0.023 | 0.32 | 0.096 | Histone deacetylase SIRT1 stimulant | 0.096 0.031 DBMET02816 | DBMET02816 | |
| 0.023 | 0.32 | 0.096 | Histone deacetylase stimulant | 0.096 0.031 DBMET02816 | DBMET02816 | |
| 0.067 | 0.364 | 0.236 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.175 0.037 DBMET02814 0.157 0.061 DBMET02815 0.19 0.024 DBMET02816 0.185 0.028 DBMET02821 0.172 0.041 DBMET02822 0.166 0.048 DBMET02823 0.236 0.008 DBMET02824 | DBMET02824 | |
| 0.06 | 0.358 | 0.41 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.258 0.054 DBMET02814 0.41 0.016 DBMET02815 0.275 0.05 DBMET02816 0.232 0.062 DBMET02821 0.166 0.099 DBMET02822 0.142 0.12 DBMET02823 0.383 0.02 DBMET02824 | DBMET02815 | |
| 0.036 | 0.335 | 0.169 | Amylase inhibitor | 0.169 0.055 DBMET02816 0.123 0.079 DBMET02822 | DBMET02816 | |
| 0.019 | 0.32 | 0.061 | NMDA receptor agonist | 0.061 0.046 DBMET02816 | DBMET02816 | |
| 0.033 | 0.335 | 0.481 | CDC-like kinase 4 inhibitor | 0.172 0.084 DBMET02814 0.481 0.008 DBMET02815 0.261 0.042 DBMET02816 0.153 0.098 DBMET02818 0.188 0.074 DBMET02821 0.277 0.038 DBMET02824 | DBMET02815 | |
| 0.019 | 0.322 | 0.05 | Heparanase inhibitor | 0.05 0.044 DBMET02816 | DBMET02816 | |
| 0.061 | 0.369 | 0.247 | 3C-like protease (Human coronavirus) inhibitor | 0.247 0.029 DBMET02815 0.227 0.038 DBMET02816 0.148 0.105 DBMET02819 | DBMET02815 | |
| 0.032 | 0.34 | 0.078 | Estrogen receptor alpha antagonist | 0.078 0.052 DBMET02816 0.07 0.067 DBMET02822 | DBMET02816 | |
| 0.033 | 0.341 | 0.14 | Psychostimulant | 0.14 0.126 DBMET02816 | DBMET02816 | |
| 0.043 | 0.352 | 0.154 | Cell wall synthesis inhibitor | 0.122 0.097 DBMET02815 0.154 0.062 DBMET02816 | DBMET02816 | |
| 0.005 | 0.315 | 0.588 | Proto-oncogene tyrosine-protein kinase Met inhibitor | 0.047 0.035 DBMET02814 0.103 0.009 DBMET02816 0.363 0.004 DBMET02821 0.21 0.004 DBMET02822 0.588 0.003 DBMET02823 0.118 0.006 DBMET02824 | DBMET02823 | |
| 0.01 | 0.321 | 0.066 | Nicotinic receptor alpha7 subunit antagonist | 0.066 0.024 DBMET02816 | DBMET02816 | |
| 0.041 | 0.354 | 0.15 | Protein kinase stimulant | 0.116 0.097 DBMET02815 0.15 0.068 DBMET02816 | DBMET02816 | |
| 0.072 | 0.386 | 0.159 | Sphingosine 1-phosphate receptor 5 antagonist | 0.159 0.048 DBMET02816 | DBMET02816 | |
| 0.017 | 0.331 | 0.085 | Insulin like growth factor 1 antagonist | 0.085 0.055 DBMET02815 0.075 0.069 DBMET02816 | DBMET02815 | |
| 0.035 | 0.351 | 0.173 | Beta amyloid protein antagonist | 0.173 0.027 DBMET02816 0.099 0.092 DBMET02824 | DBMET02816 | |
| 0.016 | 0.331 | 0.058 | ATM kinase inhibitor | 0.058 0.005 DBMET02816 | DBMET02816 | |
| 0.023 | 0.339 | 0.147 | Lck kinase inhibitor | 0.147 0.067 DBMET02816 | DBMET02816 | |
| 0.023 | 0.34 | 0.059 | Interferon inducer | 0.059 0.057 DBMET02816 | DBMET02816 | |
| 0.031 | 0.349 | 0.293 | Ribosomal protein S6 kinase inhibitor | 0.293 0.012 DBMET02815 0.128 0.083 DBMET02816 | DBMET02815 | |
| 0.037 | 0.355 | 0.211 | EphB2 antagonist | 0.211 0.08 DBMET02815 0.19 0.095 DBMET02816 0.141 0.139 DBMET02824 | DBMET02815 | |
| 0.066 | 0.386 | 0.245 | Calpain 2 inhibitor | 0.2 0.188 DBMET00863 0.195 0.192 DBMET02816 0.245 0.153 DBMET02824 | DBMET02824 | |
| 0.027 | 0.348 | 0.098 | 5 Hydroxytryptamine 2B antagonist | 0.098 0.086 DBMET02816 | DBMET02816 | |
| 0.009 | 0.33 | 0.721 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.721 0.002 DBMET02815 0.622 0.002 DBMET02818 0.587 0.002 DBMET02819 | DBMET02815 | |
| 0.011 | 0.332 | 0.049 | CC chemokine 2 receptor antagonist | 0.049 0.047 DBMET02816 | DBMET02816 | |
| 0.133 | 0.456 | 0.461 | Caspase 9 stimulant | 0.293 0.202 DBMET02815 0.461 0.077 DBMET02816 | DBMET02816 | |
| 0.011 | 0.333 | 0.124 | Glutamate receptor agonist | 0.072 0.061 DBMET02815 0.124 0.025 DBMET02816 | DBMET02816 | |
| 0.016 | 0.34 | 0.089 | Insulin growth factor antagonist | 0.089 0.056 DBMET02815 0.078 0.071 DBMET02816 | DBMET02815 | |
| 0.041 | 0.366 | 0.109 | Phosphodiesterase 6D inhibitor | 0.109 0.038 DBMET02816 0.094 0.064 DBMET02821 0.097 0.057 DBMET02822 0.091 0.072 DBMET02823 | DBMET02816 | |
| 0.022 | 0.347 | 0.084 | I kappa B kinase inhibitor | 0.084 0.056 DBMET02816 | DBMET02816 | |
| 0.055 | 0.382 | 0.164 | Hemostatic | 0.159 0.058 DBMET02815 0.164 0.053 DBMET02816 0.142 0.079 DBMET02824 | DBMET02816 | |
| 0.007 | 0.336 | 0.22 | Phosphodiesterase 2A inhibitor | 0.121 0.006 DBMET02814 0.22 0.004 DBMET02821 0.157 0.005 DBMET02822 0.139 0.005 DBMET02823 0.184 0.004 DBMET02824 | DBMET02821 | |
| 0.012 | 0.341 | 0.075 | Protein kinase C theta inhibitor | 0.075 0.018 DBMET02815 0.058 0.039 DBMET02816 | DBMET02815 | |
| 0.041 | 0.372 | 0.506 | TRKC antagonist | 0.184 0.076 DBMET02814 0.506 0.005 DBMET02815 0.314 0.023 DBMET02816 0.133 0.118 DBMET02818 0.245 0.05 DBMET02821 0.173 0.084 DBMET02822 0.134 0.117 DBMET02823 0.291 0.031 DBMET02824 | DBMET02815 | |
| 0.024 | 0.355 | 0.154 | Vascular endothelial growth factor 3 antagonist | 0.152 0.065 DBMET02815 0.154 0.063 DBMET02816 0.111 0.105 DBMET02824 | DBMET02816 | |
| 0.06 | 0.394 | 0.243 | DNA damaging | 0.243 0.085 DBMET02815 0.231 0.093 DBMET02816 | DBMET02815 | |
| 0.088 | 0.423 | 0.254 | Vasodilator, coronary | 0.197 0.185 DBMET02815 0.254 0.13 DBMET02816 | DBMET02816 | |
| 0.03 | 0.365 | 0.212 | Cyclin-dependent kinase 7 inhibitor | 0.144 0.064 DBMET02814 0.136 0.071 DBMET02815 0.196 0.035 DBMET02816 0.18 0.042 DBMET02821 0.13 0.076 DBMET02823 0.212 0.029 DBMET02824 | DBMET02824 | |
| 0.041 | 0.379 | 0.158 | Nav1.2 sodium channel blocker | 0.158 0.052 DBMET02816 | DBMET02816 | |
| 0.022 | 0.359 | 0.082 | Potassium channel (Tandem pore domain) blocker | 0.082 0.03 DBMET02816 | DBMET02816 | |
| 0.014 | 0.353 | 0.055 | Sphingosine 1-phosphate receptor 3 antagonist | 0.055 0.047 DBMET02816 | DBMET02816 | |
| 0.047 | 0.386 | 0.135 | Sphingosine 1-phosphate receptor 4 antagonist | 0.108 0.1 DBMET02815 0.135 0.049 DBMET02816 | DBMET02816 | |
| 0.006 | 0.346 | 0.023 | Histone-lysine N-methyltransferase EZH2 inhibitor | 0.023 0.007 DBMET02816 | DBMET02816 | |
| 0.019 | 0.359 | 0.059 | Heat shock protein 90 beta antagonist | 0.059 0.041 DBMET02822 | DBMET02822 | |
| 0.012 | 0.355 | 0.114 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | 0.108 0.051 DBMET02816 0.114 0.048 DBMET02824 | DBMET02824 | |
| 0.063 | 0.408 | 0.206 | 12-Lipoxygenase inhibitor | 0.206 0.145 DBMET02816 0.194 0.158 DBMET02822 | DBMET02816 | |
| 0.016 | 0.361 | 0.076 | Nav1.8 sodium channel blocker | 0.076 0.048 DBMET02816 | DBMET02816 | |
| 0.016 | 0.365 | 0.059 | I kappa B kinase 2 inhibitor | 0.059 0.049 DBMET02816 | DBMET02816 | |
| 0.061 | 0.411 | 0.188 | ATPase inhibitor | 0.162 0.081 DBMET02815 0.188 0.049 DBMET02816 | DBMET02816 | |
| 0.02 | 0.37 | 0.056 | Bombesin 3 receptor antagonist | 0.056 0.037 DBMET02815 | DBMET02815 | |
| 0.029 | 0.381 | 0.245 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.126 0.099 DBMET02814 0.239 0.028 DBMET02815 0.245 0.026 DBMET02816 0.145 0.078 DBMET02821 0.16 0.066 DBMET02822 0.183 0.051 DBMET02824 | DBMET02816 | |
| 0.073 | 0.426 | 0.169 | Growth factor agonist | 0.169 0.104 DBMET02824 | DBMET02824 | |
| 0.094 | 0.449 | 0.15 | Heat shock protein 70 antagonist | 0.133 0.108 DBMET02815 0.15 0.046 DBMET02816 | DBMET02816 | |
| 0.025 | 0.385 | 0.236 | CDC-like kinase 1 inhibitor | 0.142 0.076 DBMET02815 0.236 0.022 DBMET02816 0.118 0.097 DBMET02822 0.164 0.059 DBMET02824 | DBMET02816 | |
| 0.015 | 0.376 | 0.064 | Protein kinase C iota inhibitor | 0.064 0.036 DBMET02815 0.053 0.049 DBMET02816 | DBMET02815 | |
| 0.054 | 0.416 | 0.259 | 5 Hydroxytryptamine 1E antagonist | 0.259 0.065 DBMET02816 | DBMET02816 | |
| 0.022 | 0.387 | 0.101 | Mucolytic | 0.101 0.076 DBMET02816 | DBMET02816 | |
| 0.045 | 0.416 | 0.102 | Transforming growth factor beta 3 antagonist | 0.079 0.068 DBMET02814 0.102 0.022 DBMET02816 0.08 0.064 DBMET02821 0.089 0.039 DBMET02824 | DBMET02816 | |
| 0.005 | 0.378 | 0.029 | Cholesterol ester transfer protein antagonist | 0.029 0.025 DBMET02816 | DBMET02816 | |
| 0.005 | 0.378 | 0.08 | Tyrosine-protein kinase EMT inhibitor | 0.08 0.025 DBMET02815 0.05 0.046 DBMET02816 | DBMET02815 | |
| 0.027 | 0.4 | 0.175 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.175 0.05 DBMET02815 | DBMET02815 | |
| 0.009 | 0.383 | 0.085 | Phosphodiesterase 4B inhibitor | 0.063 0.052 DBMET02815 0.085 0.033 DBMET02816 | DBMET02816 | |
| 0.016 | 0.392 | 0.086 | Calcium antagonist | 0.086 0.058 DBMET02816 | DBMET02816 | |
| 0.017 | 0.394 | 0.111 | Glutamate (mGluR group I) antagonist | 0.111 0.022 DBMET02816 0.098 0.027 DBMET02824 | DBMET02816 | |
| 0.028 | 0.409 | 0.108 | Proteasome inhibitor | 0.108 0.077 DBMET02816 | DBMET02816 | |
| 0.043 | 0.424 | 0.15 | Interleukin 12 antagonist | 0.135 0.018 DBMET00863 0.13 0.021 DBMET00864 0.15 0.012 DBMET02817 | DBMET02817 | |
| 0.024 | 0.407 | 0.085 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.085 0.056 DBMET02816 0.076 0.071 DBMET02822 0.076 0.071 DBMET02824 | DBMET02816 | |
| 0.024 | 0.41 | 0.116 | Insulin receptor antagonist | 0.116 0.045 DBMET02815 0.087 0.082 DBMET02816 | DBMET02815 | |
| 0.011 | 0.397 | 0.069 | Sphingosine 1-phosphate receptor 4 agonist | 0.069 0.045 DBMET02816 | DBMET02816 | |
| 0.054 | 0.441 | 0.16 | Phospholipase C inhibitor | 0.16 0.087 DBMET02816 | DBMET02816 | |
| 0.007 | 0.394 | 0.05 | Nicotinic receptor beta4 subunit antagonist | 0.05 0.015 DBMET02816 | DBMET02816 | |
| 0.004 | 0.4 | 0.058 | Janus tyrosine kinase 1 inhibitor | 0.058 0.04 DBMET02824 | DBMET02824 | |
| 0.036 | 0.433 | 0.12 | Cyclooxygenase 3 inhibitor | 0.12 0.077 DBMET02816 | DBMET02816 | |
| 0.034 | 0.433 | 0.134 | mTOR complex 1 inhibitor | 0.095 0.074 DBMET02815 0.134 0.017 DBMET02816 0.103 0.056 DBMET02821 0.101 0.059 DBMET02823 0.102 0.058 DBMET02824 | DBMET02816 | |
| 0.008 | 0.408 | 0.057 | Acetylcholine M5 receptor antagonist | 0.057 0.046 DBMET02816 | DBMET02816 | |
| 0.067 | 0.468 | 0.155 | Death-associated protein kinase 1 inhibitor | 0.149 0.041 DBMET02814 0.147 0.044 DBMET02815 0.155 0.033 DBMET02816 0.133 0.072 DBMET02821 0.138 0.061 DBMET02824 | DBMET02816 | |
| 0.007 | 0.41 | 0.075 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.075 0.047 DBMET02816 | DBMET02816 | |
| 0.022 | 0.43 | 0.108 | Microtubule formation inhibitor | 0.108 0.078 DBMET02816 | DBMET02816 | |
| 0.004 | 0.417 | 0.055 | Calcitonin gene-related peptide antagonist | 0.055 0.009 DBMET02815 | DBMET02815 | |
| 0.004 | 0.417 | 0.096 | Factor XI inhibitor | 0.096 0.004 DBMET02824 | DBMET02824 | |
| 0.019 | 0.436 | 0.09 | AXL receptor tyrosine kinase inhibitor | 0.09 0.049 DBMET02816 0.074 0.07 DBMET02824 | DBMET02816 | |
| 0.061 | 0.48 | 0.308 | Cholesterol antagonist | 0.308 0.086 DBMET02816 | DBMET02816 | |
| 0.061 | 0.481 | 0.207 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.207 0.067 DBMET02815 0.174 0.101 DBMET02824 | DBMET02815 | |
| 0.026 | 0.449 | 0.093 | Bile acid receptor antagonist | 0.093 0.066 DBMET02816 | DBMET02816 | |
| 0.119 | 0.547 | 0.295 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.295 0.027 DBMET02815 0.237 0.084 DBMET02816 | DBMET02815 | |
| 0.005 | 0.433 | 0.032 | Protocollagen prolyl hydroxylase inhibitor | 0.03 0.015 DBMET02814 0.032 0.013 DBMET02816 | DBMET02816 | |
| 0.009 | 0.44 | 0.325 | p38 MAP kinase inhibitor | 0.264 0.009 DBMET02816 0.08 0.04 DBMET02821 0.325 0.006 DBMET02824 | DBMET02824 | |
| 0.016 | 0.447 | 0.458 | M18 aspartyl aminopeptidase inhibitor | 0.181 0.039 DBMET02814 0.159 0.048 DBMET02815 0.103 0.088 DBMET02822 0.458 0.004 DBMET02824 | DBMET02824 | |
| 0.051 | 0.486 | 0.113 | Vanilloid 1 agonist | 0.113 0.105 DBMET02816 | DBMET02816 | |
| 0.005 | 0.447 | 0.092 | Glutamate (mGluR5) antagonist | 0.092 0.011 DBMET02816 0.065 0.019 DBMET02824 | DBMET02816 | |
| 0.012 | 0.457 | 0.217 | Protein kinase B gamma inhibitor | 0.217 0.007 DBMET02815 0.091 0.038 DBMET02816 | DBMET02815 | |
| 0.017 | 0.462 | 0.185 | TRKB antagonist | 0.167 0.037 DBMET02815 0.185 0.03 DBMET02816 0.168 0.037 DBMET02824 | DBMET02816 | |
| 0.029 | 0.476 | 0.103 | Adenylate cyclase inhibitor | 0.103 0.081 DBMET02816 | DBMET02816 | |
| 0.011 | 0.461 | 0.114 | Janus tyrosine kinase 2 inhibitor | 0.114 0.03 DBMET02824 | DBMET02824 | |
| 0.058 | 0.511 | 0.252 | Gastrin inhibitor | 0.225 0.111 DBMET02815 0.252 0.077 DBMET02816 | DBMET02816 | |
| 0.01 | 0.473 | 0.078 | Androgen antagonist | 0.078 0.068 DBMET02815 | DBMET02815 | |
| 0.028 | 0.501 | 0.309 | Platelet antagonist | 0.148 0.147 DBMET00864 0.309 0.05 DBMET02817 | DBMET02817 | |
| 0.037 | 0.511 | 0.228 | Interleukin agonist | 0.228 0.095 DBMET02816 | DBMET02816 | |
| 0.024 | 0.5 | 0.138 | Antibacterial (Helicobacter pylori) | 0.138 0.057 DBMET02816 | DBMET02816 | |
| 0.045 | 0.521 | 0.229 | Transcription factor NF kappa B inhibitor | 0.198 0.17 DBMET02816 0.229 0.143 DBMET02822 | DBMET02822 | |
| 0.025 | 0.503 | 0.092 | Hedgehog signaling inhibitor | 0.091 0.083 DBMET02814 0.092 0.081 DBMET02824 | DBMET02824 | |
| 0.005 | 0.484 | 0.182 | Janus tyrosine kinase 3 inhibitor | 0.099 0.034 DBMET02816 0.182 0.014 DBMET02824 | DBMET02824 | |
| 0.019 | 0.506 | 0.065 | I kappa B kinase 1 inhibitor | 0.065 0.057 DBMET02816 | DBMET02816 | |
| 0.005 | 0.497 | 0.163 | Phosphodiesterase 3B inhibitor | 0.163 0.005 DBMET02815 0.042 0.033 DBMET02821 0.063 0.019 DBMET02822 | DBMET02815 | |
| 0.039 | 0.533 | 0.193 | Transcription factor STAT3 inhibitor | 0.193 0.144 DBMET02816 | DBMET02816 | |
| 0.02 | 0.517 | 0.147 | MAP kinase 12 inhibitor | 0.147 0.044 DBMET02815 0.114 0.077 DBMET02816 | DBMET02815 | |
| 0.024 | 0.521 | 0.12 | Interleukin 8 antagonist | 0.12 0.061 DBMET02816 | DBMET02816 | |
| 0.011 | 0.509 | 0.115 | ALK inhibitor | 0.115 0.032 DBMET02815 0.102 0.04 DBMET02816 | DBMET02815 | |
| 0.006 | 0.508 | 0.105 | Phosphodiesterase 4C inhibitor | 0.055 0.04 DBMET02814 0.105 0.014 DBMET02816 | DBMET02816 | |
| 0.014 | 0.517 | 0.084 | Caspase 7 inhibitor | 0.084 0.052 DBMET02816 | DBMET02816 | |
| 0.011 | 0.516 | 0.133 | Glutamate (mGluR) antagonist | 0.133 0.021 DBMET02816 0.122 0.025 DBMET02824 | DBMET02816 | |
| 0.009 | 0.514 | 0.293 | Phosphodiesterase III inhibitor | 0.063 0.049 DBMET02814 0.293 0.004 DBMET02815 0.084 0.032 DBMET02818 0.071 0.043 DBMET02819 0.069 0.044 DBMET02822 | DBMET02815 | |
| 0.031 | 0.539 | 0.243 | Polo-like kinase-3 inhibitor | 0.201 0.044 DBMET02814 0.243 0.026 DBMET02815 0.198 0.046 DBMET02816 0.139 0.097 DBMET02819 0.135 0.103 DBMET02824 | DBMET02815 | |
| 0.038 | 0.556 | 0.186 | Tumour necrosis factor antagonist | 0.186 0.062 DBMET02815 0.165 0.082 DBMET02816 | DBMET02815 | |
| 0.004 | 0.526 | 0.056 | Secretase gamma inhibitor | 0.056 0.022 DBMET02816 | DBMET02816 | |
| 0.01 | 0.538 | 0.149 | MAP kinase 8 inhibitor | 0.149 0.03 DBMET02815 0.129 0.038 DBMET02816 | DBMET02815 | |
| 0.052 | 0.594 | 0.188 | Lipocortins synthesis antagonist | 0.139 0.123 DBMET00864 0.136 0.128 DBMET02814 0.188 0.065 DBMET02816 0.171 0.079 DBMET02817 0.163 0.088 DBMET02822 | DBMET02816 | |
| 0.025 | 0.574 | 0.187 | Antiamyloidogenic | 0.187 0.109 DBMET02816 | DBMET02816 | |
| 0.024 | 0.575 | 0.082 | MAP kinase kinase 8 inhibitor | 0.082 0.033 DBMET02815 0.072 0.043 DBMET02816 0.062 0.059 DBMET02821 0.078 0.036 DBMET02824 | DBMET02815 | |
| 0.038 | 0.591 | 0.206 | Transcription factor STAT inhibitor | 0.206 0.13 DBMET02816 | DBMET02816 | |
| 0.029 | 0.584 | 0.177 | Antipruritic | 0.177 0.067 DBMET02816 | DBMET02816 | |
| 0.05 | 0.61 | 0.148 | Death-associated protein kinase 2 inhibitor | 0.148 0.111 DBMET02815 | DBMET02815 | |
| 0.014 | 0.584 | 0.086 | Interleukin 1 beta converting enzyme inhibitor | 0.086 0.079 DBMET02816 | DBMET02816 | |
| 0.007 | 0.58 | 0.044 | Acetyl-CoA carboxylase inhibitor | 0.044 0.025 DBMET02815 | DBMET02815 | |
| 0.012 | 0.593 | 0.073 | Transcription factor AP-1 inhibitor | 0.058 0.048 DBMET02816 0.073 0.027 DBMET02820 | DBMET02820 | |
| 0.05 | 0.643 | 0.304 | Sodium/bile acid cotransporter inhibitor | 0.253 0.125 DBMET00864 0.302 0.077 DBMET02815 0.25 0.128 DBMET02816 0.304 0.075 DBMET02817 0.257 0.12 DBMET02822 | DBMET02817 | |
| 0.005 | 0.603 | 0.127 | Factor XIa inhibitor | 0.038 0.032 DBMET02815 0.037 0.033 DBMET02816 0.127 0.004 DBMET02824 | DBMET02824 | |
| 0.005 | 0.617 | 0.339 | Bromodomain-containing protein 4 inhibitor | 0.052 0.042 DBMET02814 0.057 0.036 DBMET02815 0.339 0.003 DBMET02821 0.245 0.004 DBMET02822 0.078 0.02 DBMET02823 | DBMET02821 | |
| 0.008 | 0.627 | 0.078 | Toll-Like receptor 7 antagonist | 0.078 0.039 DBMET02824 | DBMET02824 | |
| 0.053 | 0.673 | 0.707 | Antiinflammatory | 0.431 0.12 DBMET00864 0.482 0.095 DBMET02815 0.495 0.09 DBMET02816 0.591 0.056 DBMET02821 0.609 0.051 DBMET02822 0.707 0.03 DBMET02823 0.599 0.054 DBMET02824 | DBMET02823 | |
| 0.008 | 0.633 | 0.186 | M17 leucyl aminopeptidase inhibitor | 0.175 0.042 DBMET02814 0.186 0.038 DBMET02815 0.136 0.064 DBMET02819 | DBMET02815 | |
| 0.047 | 0.679 | 0.283 | Caspase 3 stimulant | 0.283 0.088 DBMET02816 | DBMET02816 | |
| 0.021 | 0.664 | 0.138 | Phosphodiesterase 7B inhibitor | 0.111 0.044 DBMET02814 0.138 0.026 DBMET02821 0.128 0.032 DBMET02824 | DBMET02821 | |
| 0.004 | 0.661 | 0.021 | Dopamine D1 agonist | 0.021 0.019 DBMET02815 | DBMET02815 | |
| 0.008 | 0.669 | 0.11 | Topoisomerase II inhibitor | 0.11 0.077 DBMET02816 | DBMET02816 | |
| 0.006 | 0.669 | 0.062 | CDC25B inhibitor | 0.062 0.048 DBMET02816 | DBMET02816 | |
| 0.005 | 0.669 | 0.236 | Bromodomain-containing protein 3 inhibitor | 0.057 0.024 DBMET02814 0.236 0.003 DBMET02821 0.179 0.003 DBMET02822 0.087 0.007 DBMET02823 | DBMET02821 | |
| 0.008 | 0.68 | 0.155 | Bronchodilator | 0.114 0.049 DBMET02815 0.111 0.052 DBMET02821 0.155 0.03 DBMET02822 0.114 0.049 DBMET02823 0.084 0.081 DBMET02824 | DBMET02822 | |
| 0.005 | 0.687 | 0.073 | Glutamate (mGluR) agonist | 0.073 0.034 DBMET02816 | DBMET02816 | |
| 0.004 | 0.732 | 0.073 | Phosphodiesterase 4A inhibitor | 0.073 0.023 DBMET02814 0.045 0.038 DBMET02816 | DBMET02814 | |
| 0.025 | 0.774 | 0.348 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.255 0.102 DBMET02814 0.348 0.037 DBMET02815 0.304 0.061 DBMET02816 | DBMET02815 | |
| 0.012 | 0.764 | 0.084 | Phosphodiesterase VIII inhibitor | 0.073 0.047 DBMET02821 0.084 0.028 DBMET02823 | DBMET02823 | |
| 0.002 | 0.757 | 0.025 | Thyroid hormone alpha agonist | 0.025 0.005 DBMET02815 0.016 0.011 DBMET02818 | DBMET02815 | |
| 0.012 | 0.767 | 0.513 | Tumour necrosis factor alpha release inhibitor | 0.241 0.079 DBMET00863 0.183 0.124 DBMET02815 0.513 0.013 DBMET02816 0.202 0.107 DBMET02821 0.225 0.089 DBMET02822 | DBMET02816 | |
| 0.008 | 0.77 | 0.251 | Potassium channel blocker | 0.251 0.066 DBMET02824 | DBMET02824 | |
| 0.005 | 0.775 | 0.17 | Glutamate receptor antagonist | 0.158 0.046 DBMET02815 0.17 0.039 DBMET02816 | DBMET02816 | |
| 0.02 | 0.799 | 0.378 | Nootropic | 0.258 0.101 DBMET02815 0.378 0.045 DBMET02816 | DBMET02816 | |
| 0.003 | 0.808 | 0.505 | Poly(ADP-ribose) polymerase 2 inhibitor | 0.505 0.003 DBMET02815 0.182 0.004 DBMET02818 0.093 0.005 DBMET02819 | DBMET02815 | |
| 0.004 | 0.817 | 0.101 | Phosphodiesterase 4D inhibitor | 0.101 0.036 DBMET02816 | DBMET02816 | |
| 0.007 | 0.826 | 0.085 | Phosphodiesterase XI inhibitor | 0.085 0.049 DBMET02821 | DBMET02821 | |
| 0.007 | 0.826 | 0.085 | Phosphodiesterase 11A inhibitor | 0.085 0.049 DBMET02821 | DBMET02821 | |
| 0.058 | 0.889 | 0.292 | Calcium channel L-type activator | 0.244 0.212 DBMET02814 0.292 0.164 DBMET02823 | DBMET02823 | |
| 0.01 | 0.857 | 0.081 | Antiviral (Hepatitis D) | 0.081 0.008 DBMET02815 | DBMET02815 | |
| 0.026 | 0.895 | 0.154 | Growth hormone agonist | 0.154 0.084 DBMET02817 | DBMET02817 | |
| 0.004 | 0.88 | 0.059 | Leukotriene synthesis inhibitor | 0.059 0.057 DBMET02817 | DBMET02817 | |
| 0.005 | 0.902 | 0.064 | Potassium channel (Ca-activated) blocker | 0.06 0.041 DBMET02816 0.055 0.054 DBMET02821 0.064 0.035 DBMET02824 | DBMET02824 | |
| 0.003 | 0.904 | 0.052 | Potassium channel (Inward rectifier) 1 blocker | 0.052 0.004 DBMET02824 | DBMET02824 | |
| 0.02 | 0.927 | 0.099 | Folate antagonist | 0.099 0.067 DBMET02817 | DBMET02817 | |
| 0.01 | 0.919 | 0.091 | Nav1.1 sodium channel blocker | 0.091 0.079 DBMET02816 | DBMET02816 | |
| 0.005 | 0.915 | 0.259 | Toll-Like receptor 7 agonist | 0.259 0.14 DBMET02824 | DBMET02824 | |
| 0.002 | 0.917 | 0.026 | Vasopressin 1A antagonist | 0.026 0.022 DBMET02821 | DBMET02821 | |
| 0.005 | 0.92 | 0.249 | Toll-Like receptor agonist | 0.249 0.15 DBMET02824 | DBMET02824 | |
| 0.005 | 0.923 | 0.441 | Analgesic | 0.441 0.068 DBMET02816 | DBMET02816 | |
| 0.005 | 0.93 | 0.048 | 5 Hydroxytryptamine 1B agonist | 0.048 0.046 DBMET02824 | DBMET02824 | |
| 0.007 | 0.947 | 0.148 | Platelet adhesion inhibitor | 0.148 0.108 DBMET00863 | DBMET00863 | |
| 0.004 | 0.945 | 0.094 | 5-Lipoxygenase inhibitor | 0.094 0.068 DBMET00864 | DBMET00864 | |
| 0.005 | 0.958 | 0.333 | Cyclophilin D inhibitor | 0.333 0.135 DBMET00864 | DBMET00864 | |
| 0.005 | 0.963 | 0.205 | Immunomodulator | 0.205 0.158 DBMET02816 | DBMET02816 | |
| 0.004 | 0.965 | 0.117 | Estrogen receptor beta antagonist | 0.117 0.036 DBMET02822 | DBMET02822 | |
| 0.022 | 0.988 | 0.212 | Interleukin 2 agonist | 0.212 0.169 DBMET02817 | DBMET02817 | |
| 0.005 | 0.98 | 0.335 | Hypoglycemic | 0.335 0.041 DBMET00864 | DBMET00864 | |
| 0.004 | 0.98 | 0.128 | Estrogen antagonist | 0.128 0.041 DBMET02822 | DBMET02822 | |
| 0.004 | 0.991 | 0.129 | Viral attachment inhibitor | 0.129 0.012 DBMET02824 | DBMET02824 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |